Systems/Circuits

# Spinal Glycine Receptor Alpha 3 Cells Communicate Sensations of Chemical Itch in Hairy Skin

### <sup>®</sup>Hannah M. Weman, <sup>®</sup>Mikaela M. Ceder, <sup>®</sup>Aikeremu Ahemaiti, <sup>®</sup>Kajsa A. Magnusson, <sup>®</sup>Katharina Henriksson, <sup>®</sup>Linn Andréasson, and <sup>®</sup>Malin C. Lagerström

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 75108, Sweden

Glycinergic neurons regulate nociceptive and pruriceptive signaling in the spinal cord, but the identity and role of the glycineregulated neurons are not fully known. Herein, we have characterized spinal glycine receptor alpha 3 (*Glra3*) subunit-expressing neurons in *Glra3*-Cre female and male mice. *Glra3*-Cre(+) neurons express *Glra3*, are located mainly in laminae III–VI, and respond to glycine. Chemogenetic activation of spinal *Glra3*-Cre(+) neurons induced biting/licking, stomping, and guarding behaviors, indicative of both a nociceptive and pruriceptive role for this population. Chemogenetic inhibition did not affect mechanical or thermal responses but reduced behaviors evoked by compound 48/80 and chloroquine, revealing a pruriceptive role for these neurons. Spinal cells activated by compound 48/80 or chloroquine express *Glra3*, further supporting the phenotype. Retrograde tracing revealed that spinal *Glra3*-Cre(+) neurons receive input from afferents associated with pain and itch, and dorsal root stimulation validated the monosynaptic input. In conclusion, these results show that spinal *Glra3*(+) neurons contribute to acute communication of compound 48/80- and chloroquine-induced itch in hairy skin.

Key words: chemogenetics; glycine; itch; retrograde tracing; spinal cord

### Significance Statement

Spinal glycinergic neurons regulate itch (pruriception), suggesting that components of the glycinergic system have great potential as drug targets to treat pruritus. Nonetheless, thus far, the pruriceptive roles of any of the glycine receptor (GLR) subunits have not been evaluated. Here, we successfully linked the *Glra3*-Cre populations to a pro-pruriceptive role in itch, indicating that GLRA3-expressing neurons may be a potential novel target for itch treatment. The spontaneous stomping and guarding behaviors observed from activating the *Glra3*-Cre populations are indicative of a role in sensory hypersensitivity and hence, raises questions regarding the hypersensitivity involvement of these populations for future investigations.

Received Aug. 22, 2023; revised Jan. 31, 2024; accepted Feb. 15, 2024.

The authors declare no competing financial interests.

Correspondence should be addressed to Malin C. Lagerström at malin.lagerstrom@igp.uu.se. https://doi.org/10.1523/JNEUROSCI.1585-23.2024

Copyright © 2024 Weman et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0

International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

#### Introduction

Spinal somatosensory circuits transmitting the sensation of pain and itch from the body are regulated locally by inhibitory inputs, including glycinergic transmission (Beyer et al., 1985; Yamamoto and Yaksh, 1993; Takazawa et al., 2017; Freitag et al., 2019). For instance, ablation of glycine transporter 2 (GLYT2) neurons results in mechanical, heat, and cold hyperalgesia and behaviors associated with persistent itch, for example, extensive localized biting (Foster et al., 2015). Conversely, selective activation of GLYT2 neurons in vivo reduces the sensitivity to mechanical-, heat-, and cold-induced pain and the behavioral responses against chloroquine and histamine, suggesting that the glycinergic system is essential for controlling pain and itch transmission (Foster et al., 2015). In addition, the glycinergic system is activated by nociceptive counter stimuli, which decrease itch transmission in the spinal cord (Akiyama et al., 2011).

Author contributions: H.M.W., M.M.C., and M.C.L. designed research; H.M.W., M.M.C., A.A., K.A.M., K.H., L.A., and M.C.L. performed research; H.M.W., M.M.C., and A.A. analyzed data; H.M.W., M.M.C., A.A., and M.C.L. wrote the paper.

We thank Jonne Rietdijk and Jon Jakobsson for technical assistance, Stina Lundberg for statistical analysis input, Elena Muscolino for proofreading, and Caroline Öhman-Mägi for technical assistance prior to the 3D printing of the artificial hindpaw. The 3D printing was performed at U-PRINT: Uppsala University's 3D printing facility at the Disciplinary Domain of Medicine and Pharmacy. Uppsala University Behavioral Facility (UBF) for virus facility and behavioral tests support, and the Biological Visualization (BioVis) core at the department of Immunology, Genetics and Pathology (IGP), Uppsala University, for confocal imaging support. We thank the Viral Core Facility (VCF, Charité, Berlin) for the production of the helper and pseudotyped rabies viruses. This work was supported by the Swedish Brain Foundation, the Swedish Research Council (2016-00851, 2022-00960), Knut och Alice Wallenbergs Stiftelse (2019.0047; dorsal root stimulations), and Uppsala University.

Glycinergic receptors (GLRs) are ligand-gated ion channels, which induce inward hyperpolarizing chloride currents upon binding of glycine (Lynch, 2004; Zeilhofer, 2005; Lein et al., 2007; Dutertre et al., 2012). In mice, the glycine receptor alpha 3 (Glra3) gene is expressed in both excitatory and inhibitory spinal dorsal horn neuronal clusters (Häring et al., 2018; Zeisel et al., 2018; Ceder et al., 2023) and GLRA3 immunoreactivity is detected in the dorsal (Harvey et al., 2004; Wang et al., 2018; Werynska et al., 2021) and ventral horns of the spinal cord (Harvey et al., 2004; Wang et al., 2018). The other Glr genes, Glra1, Glra2, Glra4, and Glrb, are also expressed in the dorsal horn of the spinal cord (Groemer et al., 2022). In addition to the expression in the spinal cord, Glra3 is detected in the amygdala, hypothalamus, nucleus accumbens, tegmentum, and brainstem, but not in the dorsal root ganglia (DRG; Lein et al., 2007; Usoskin et al., 2015; McCracken et al., 2017; Häring et al., 2018; Tudeau et al., 2020; San Martin et al., 2021; Groemer et al., 2022). Expression analyses have shown that spinal cord injury decreases levels of GLRA3 in the dorsal spinal cord, whereas zymosan A-induced inflammation increases GLRA3 levels (Berrocal et al., 2014; Mariqueo, 2020). Additionally, in an endometriosis mouse model, Glra3 expression was found to be upregulated in the insula (Li et al., 2018), emphasizing this receptor subunit's role in pain and its potential as a novel pain treatment.

Thus far, studies have focused on examining the nociceptive role of the GLRA3 subunit. Herein, we investigated the molecular and electrophysiological characteristics, along with the sensory role of spinal *Glra3*-expressing cells in pruriceptive, mechanical, and thermal transmission, using a transgenic *Glra3*-Cre mouse line and *fos* measurements. Moreover, we established neuronal inputs to the population, using replication deficient rabies tracing and dorsal root stimulations.

### Materials and Methods

#### Animals

Procedures related to the mice used in this study were approved by the local animal research ethical committee (Uppsala djurförsöksetiska nämnd) and followed the Swedish Animal Welfare Act [Svensk författningssamling (SFS) 2018:1192], the Swedish Animal Welfare Ordinance (SFS 2019:66), and the Regulations and General Advice for Laboratory Animals (SJVFS 2019:9, Saknr L 150), permit numbers: 5.8.18-01428/2023, 5.2.18-17971/2019, 5.8.18-11551/2019, 5.8.18-19421/2019, 5.8.18-01217/2019, 5.8.18-01503/2023 and 5.8.18-03266/ 2023. The constitutive knock-in Glra3-Cre mouse line was generated by Cyagen, with the homology arms having been amplified from a bacterial artificial chromosome (BAC), for which the Glra3 gene is located on chromosome 8 (GenBank: NM\_080438.2, Ensembl: ENSMUS0000038257). Glra3-Cre(+) mice were crossed with C57BL/ 6J mice (Taconic) and *tdTomato* reporter mice [Gt(ROSA) 26Sor<sup>tm14(CAG-tdTomato)Hze</sup>, Allen Brain Institute]. The *Glra3*-Cre allele was kept hemizygous and both female and male mice were included in the analyses, unless otherwise stated. The mice were housed with littermates in  $\sim$ 501 cm<sup>2</sup> cages (maximum five mice per cage) in room temperature (RT) ranging between 20 and 24°C and humidity of 45-65% on a 12 h light/dark cycle with lights on at 6 A.M. All mice were provided food (Diet Pellets, Scanbur) and tap water ad libitum.

### Genotyping by polymerase chain reaction

Tissue biopsies from ear marking, taken at the age of 3-4 weeks, were incubated in 50 µl of buffer, consisting of 25 mM NaOH and 200 µM ethylenediaminetetra-acetic acid (EDTA), in a shaking block (BIOER Mixing Block MB-102, 300 speed) at 96°C for 25 min, whereafter the samples were neutralized with 50 µl of Tris-HCl (40 mM), pH 8.0. The following primers were used to identify *Cre* and *tdTomato*,

respectively; *Cre* 5'-acgagtgatgaggttcgcaaga-3' (forward, mutant allele), 5'-accgacgatgaagcatgtttag-3' (reverse, mutant allele), *tdTomato* 5'-c tgttcctgtacggcatgg-3' (forward, mutant allele), 5'-ggcattaaagcagcgtatcc-3' (reverse, mutant allele), 5'-aagggagctgcagtggagta-3' (forward, wild-type allele), 5'-ccgaaaatctgtgggaagtc-3' (reverse, wild-type allele).

#### Spinal cord viral injections

The viral injections into the spinal cord were performed for the chemogenetic sensory tests, monosynaptic retrograde tracing, and the electrophysiological recordings of adult Glra3-Cre(+) neurons. The injections were performed as previously described (Freitag et al., 2019); in brief, Glra3-Cre mice (>6 weeks old) were initially anesthetized in a 4% isoflurane (FORANE, Baxter) box. When fully anesthetized, the mice were moved to a stereotaxic frame with a breathing mask, where the isoflurane concentration was kept at 1.5-2% throughout the entire procedure. To prevent eye damage, Oftagel was applied (Santen Oy), and the body temperature was monitored and maintained at 35-37°C using a heating pad (FHC). Adjacent to the incision sites, the mice were administered subcutaneously with bupivacaine (Marcain, 2 mg/kg, AstraZeneca). For postsurgery analgesia, the mice were administered subcutaneously with carprofen (Norocarp vet, 5 mg/kg, N-vet, or Rimadyl Bovis vet, 4 mg/kg, Zoetis Finland Oy). Within 24 h postsurgery, the mice were again administered 4-5 mg/kg carprofen for postsurgery analgesia. The dorsal skin was shaved and cleaned with sterile saline (B Braun Medical) and chlorhexidine (Fresenius Kabi) before a 1 cm skin incision was made to expose the T13 and L1 vertebrae. Sterile saline was continuously applied to keep the tissue moist. The connective tissue was gently separated along these vertebrae, and a clamp was inserted ventral of the L1 transverse process for stabilization of the spine. When stabilized, the posterior longitudinal ligament and ligamentum flavum connecting T13 and L1 were cut to expose the spinal cord. Thereafter, 500 nl of the respective viral vector [AAV8.hSyn-DIO-hM3D(Gq)-mCherry (Krashes et al., 2011), AAV8.hSyn-DIO-mCherry, or AAVDJ.EF1a-DIO-HTB; please see Table 1 for detailed information] was injected into the L5/L6 spinal dorsal horn (as caudal as possible from zeroed midline, ML, 0.4 mm; DV, 0.4 mm; with needle eye directed rostrally), using a 10 µl NanoFil Hamilton syringe (World Precision Instruments) with a 34 g beveled needle (World Precision Instruments), monitored by a micro syringe pump controller (World Precision Instruments) at 50 nl/min. For injections of AAV8.hSyn-DIO-hM4D(Gi)-mCherry (Krashes et al., 2011), the virus was injected at two sites into the right dorsal horn (RC, 0/-0.5 mm; ML, 0.3 mm; DV, 0.6 mm), with the eye of the needle pointing lateral. To prevent leakage and withdrawal of virus, the needle was left in the injection site for 5 min. When the injection was completed, the spine was detached from the clamp, and the connective tissue and skin were sutured and cleaned with sterile saline before the mice were removed from the breathing mask and administered subcutaneously with Buprenorphine (Vetergesic Vet, Orion Pharma, 0.05 mg/kg). The mice were subsequently placed on a heating pad in their cages to wake up. The mice were subjected to behavioral experiments or killed for tissue analyses after a minimum of 2-4 weeks to allow sufficient expression of viral genes.

Adult *Glra3*-Cre mice (7 + 7, 7 females, 7 males, 6–26 weeks old) for the Randall–Selitto test were injected with *AAV8.hSyn-DIO-hM4D(Gi)mCherry* (Krashes et al., 2011) or *AAV8.hSyn-DIO-mCherry* between L1/L2 to target the sacral 2 (S2) segment, affecting the tail (Bennett et al., 1999). The virus was injected into the dorsal horn at two sites with the eye of the needle directing laterally (RC, 0/–0.5 mm; ML, 0.25 mm; DV, 0.45 mm). The mice were assessed to the Randall–Selitto test 2–3 weeks after injection.

The injections for monosynaptic retrograde tracing of adult *Glra3*-Cre mice (*Glra3*-Cre(+): 5 females, 5 males, 7–15 weeks old; *Glra3*-Cre(-): 3 females, 3 males, 7–17 weeks old) were conducted in the same manner as described above for the AAV8.hSyn-DIO-hM3D(Gq)-mCherry experiments. The mice were initially injected with helper virus (herein abbreviated as AAV8.Syn-flex-TVA-oG-GFP). To allow sufficient expression of the helper vector genes required for rabies virus host cell entry, the mice were injected with pseudotyped rabies virus *BRVenvA-10 Rabies Virus, pseudotyped EnvA, mCherry* (please see

Table 1. Key resources table					
Viral vectors and serotypes					
	Vector	Source	Company	Lot and titer	Injection
AAV8.hSyn-DIO-hM3D(Gq)-mCherry	pAAV-hSyn-DIO-hM3D(Gq)-mCherry	The vector was a gift from Bryan Roth (Krashes et al., 2011; Addgene viral prep #44361-AAV8; http://n2t.net/addgene:44361; RRID:Addgene_44361)	Addgene	First lot#: v27924 with titer: 2.2 $\times$ 10 <sup>13</sup> GC/ml; second lot # v78582 with titer: 2.1 $\times$ 10 <sup>13</sup> GC/ml	One site
AAV8.hSyn-DIO-hM4D(Gi)-mCherny	pAAV-hSyn-hM4D(Gi)-mCherry	The vector was a gift from Bryan Roth (Krashes et al., 2011; Addgene viral prep #44362-AAV8; http://n-rr.net/addnene:043572- BRD-Addaene_043550	Addgene	v86749 with titer: $1.8 \times 10^{13}$ GC/ml	Two sites
AAV8.hSyn-DIO-mCherry	pAAV-hSyn-DIO-mCherry	interministic reasonage in the second s	Addgene	v61605 with titer: $2.2 \times 10^{13}$ GC/ml	One or two sites (unilateral)
AAVDJ.EFTa-DIO-HTB	pAAV.EF1a-DIO-HTB	The vector was a gift from Edward Callaboration (Addgene plasmid # 44187; http://n2t.net/ addgene:44187; RRID:Addgene_44187). The vector was packaged into AAVDI by Salk institute GT3 (Gene Transfer, Targeting, and Therapeutics) core facility (provided by John Naughton) with funding from NIH-NG CGG: P30 014195, an NINDS R24 Core Grant and	Salk Institute	Lot date: 20/12-2018 with titer: 1.09 $\times$ 10 <sup>12</sup> VG/ml	Two sites (bilateral)
AAV8.Syn-flex-TVA.E66T-P2A-oG-WPRE3	pAAV.Syn-flex-TVA.E66T-P2A-oG-WPRE3	unung roun ver Charité, with technical assistance from Salk investigator John Naughton	Charité	BA-229a with titer: 3.98 $ imes$ 10 <sup>12</sup> VG/	One site
BRVenvA-1o Rabies Virus, pseudotyped EnvA, mCherry	pSADB19dG-mCherry	Charité, the material was originally provided by Edward Callaway and distributed through Addgene (plasmid #32630, #32631, #32632, #32633, #32634; Osakada et al., 2011)	Charité	unknown, with titer: 1.00 × 10 <sup>8</sup> particles/ml	One site
Antibodies					
Antibody name	Host animal	Dilution	Company	Catalog number	Lot
NEUN	Mouse	1:500-1:1,000	Millipore	MAB377	
PKCy IBA	Rabbit polyclonal	1:500	Santa Cruz Biotechnology	sc-211 132450	
	Babhit nolvclonal	1.500	(nvanre/Riol egend		
GFP	Chicken	1:1,000	Aves Labs	GFP-1020	
NF200	Rabbit	1:1,000	Sigma-Aldrich	N4142	
TRKA	Rabbit monoclonal	1:1,000	Abcam	ab8871	
CGRP Tu	Rabbit polyclonal	1:1,000	Peninsula Laboratories	T-4239.0050	
LIN SST	kaboit Rahhir nolvclonal	1:1,000 1-500	Millipore Invitroren	AB 152 X 1371918	PA5-85759
Anti-rabbit 488	Goat	1:500	Jackson ImmunoResearch	111-095-144	
Anti-rabbit 647	Donkey	1:200 (SST assay); 1:500	Invitrogen	A31573	
Anti-mouse 488	Donkey	1:200	Abcam	ab150105	
Anti-mouse 04/ Anti-chicken 488	Jonkey Donkey	1:500	invitrogen Invitrogen	A31571 SA1-72000	
RNAscope probes					
Probe name		Dilution	Company	Catalog number	Channel
fos		1:50	Advanced Cell Diagnostics	31692	CI
Glra3		1:50	Advanced Cell Diagnostics	490591	0
mCherry		1:50	Advanced Cell Diagnostics	431201	05
Mrapro Mrapro3		001 150	Advanced Cell Diagnostics	120224	5 0
Mrgprd		1:50	Advanced Cell Diagnostics	417921	C1
Trpm8		1:50	Advanced Cell Diagnostics	420451	0 2
Ι ναμιτ		05:1 13:10	Advanced Cell Diagnostics	166515	ວ ຕ
r giute Viaat		1:50	Advanced Cell Diagnostics	319191	00

Table 1 for detailed information) 7–8 d after the helper virus injection. One week after the final injection, the mice were sacrificed.

## *Immunohistochemistry tissue preparation of developmental and adult virally labeled Glra3-Cre(+) mice*

Adult Glra3-Cre;tdTomato mice (4 females, 7-23 weeks old) and virally spinal cord injected Glra3-Cre.mCherry mice (2 females, 2 males, 17-25 weeks old, from the behavioral experiments) were anesthetized in isoflurane (FORANE, Baxter). All mice were subsequently injected intraperitoneally with 0.6 ml (1:1) ketamine (Ketalar, 10 mg/ml, Pfizer) and medetomidine (Domitor, 1 mg/ml, Orion Pharma). When fully anesthetized, the mice were perfused through the left ventricle with  $1 \times$ PBS, followed by 4% formaldehyde (FA; Histolab). The spinal columns were isolated and placed in 1× PBS, followed by dissection of the tissue area of interest (spinal cord and DRG). The tissues were placed in 4% FA (Histolab) at 4°C overnight. The spinal cords and DRG were dehydrated for 24 h in 15% sucrose and then for 24 h in 30% sucrose for cryoprotection. The tissues were thereafter embedded in optimal cutting temperature (OCT) medium (Bio-Optica) and snap-frozen on dry ice in -80°C isopentane (Sigma-Aldrich), at which temperature the tissues were stored until sectioning. The spinal cords and DRG were sectioned into 16-18 µm sections using a cryostat (Leica Cryocut 1800, Leica), and the sections were collected on glass slides (Superfrost Plus, Thermo Fisher Scientific) as a series of six slides/series. The completed slides were stored at -80°C until further immunohistochemical analyses were performed.

In the tracing experiment, following brain dissections, the brains were fixated in 4% FA (Histolab) at 4°C overnight and thereafter stored in 1× PBS at 4°C until vibratome sectioning. Upon sectioning, the brains were superficially and unilaterally cut with a razor blade to keep track of orientation and subsequently mounted in 4% agarose. The brains were sliced into 70  $\mu$ m sections (Leica VT1000S, Leica), which were collected into wells as series of five wells/series with five sections/well. All sections were examined for traced mCherry(+) cells using a fluorescent stereomicroscope (Leica MZ16F, Leica). For documentation, the brain sections of one well/series (every fifth brain section) were mounted and embedded in Anti-Fade Fluorescence Mounting Medium (Abcam) on glass slides and covered with glass cover slides (Menzel-Gläser) for imaging.

#### Immunohistochemistry

All slides to be used for immunohistochemistry (Glra3-Cre;tdTomato: 4 females, 7-23 weeks old; Glra3-Cre.mCherry: 4 mice; 2 females, 2 males, 17-25 weeks old; traced Glra3-Cre(+): 4 females, 2 males, 9-17 weeks old) were placed at RT for 30 min to thaw and dry before initializing the protocols. The assays were either PBS- (NEUN, PKCy, IB4, NF200, TRKA, CGRP, TH) or TBS- (PAX2, SST) based. In all assays, the sections were washed with  $1 \times PBS/TBS$  for  $4 \times 10$  min before and after the primary antibody incubation. Prior to the primary antibody incubation, the sections were blocked with either supermix [0.25% gelatin and 0.5% Triton X-100 in 1× PBS/TBS (NEUN, NF200, TRKA, CGRP, TH)] or blocking solution [5% donkey or goat serum in 1× PBS/TBS (PKCy, IB4, PAX2, SST)] for 1 h at RT. In the same solutions [supermix: (PKCy, IB4, PAX2, SST); blocking solution: (NEUN, NF200, TRKA, CGRP, TH)], the primary and secondary antibodies were incubated, in which the primary antibodies were incubated for 48 h at 4°C and the secondary antibodies with 200 nM/ml DAPI for 2 h at RT. As the final step, the sections were washed 4× 10 min in 1× PBST/TBST (0.1% Tween 20 in 1× PBS/TBS). After completion of protocols, the slides were embedded in Anti-Fade Fluorescence Mounting Medium (Abcam) and covered with glass slides (Menzel-Gläser). The slides were left at 4°C to dry and were stored at this temperature until imaging. For antibody specifics, see Table 1.

#### In situ hybridization tissue preparation

Adult *Glra3*-Cre(+) mice microinjected with AAVDJ.EF1a-DIO-HTB (3 females, 2 males, 7–11 weeks) and mice included in the retrograde rabies tracing (1 female and 2 males, 14 weeks) in the L5/L6 spinal dorsal horn were subjected to similar procedures as described previously (Freitag et al., 2021). The HTB protein is a histone-tagged GFP, and this virus was used since the fluorescence could be detected after RNAscope

protocol. In brief; 14 d postviral injection, the mice were anesthetized in isoflurane (FORANE, Baxter), followed by intraperitoneal injection of 0.6 ml (1:1) ketamine (Ketalar, 10 mg/ml, Pfizer) and medetomidine (Domitor, 1 mg/ml, Orion Pharma). To minimize the risk of contamination and altered gene expression, the mice were perfused in autoclaved ice-cold  $1 \times$  PBS. In the same solution, the spinal columns were quickly dissected, and the spinal area containing the viral fluorescence was isolated. The tissues were immediately embedded in OCT medium (Bio-Optica) and snap-frozen on dry ice in -80°C isopentane (Sigma-Aldrich), at which temperature the tissues were stored until sectioning. The tissues were cryosectioned (Leica Cryocut 1800, Leica) into 12-14 µm sections and were collected onto Superfrost Plus (Thermo Fisher Scientific) glass slides as series consisting of six slides with 7-8 sections/slide for the Glra3-Cre(+) AAVDJ.EF1a-DIO-HTB injected mice and eight slides with 3 sections/slide for the sensory stimulated C57BL/6J mice. To prevent mRNA degradation and contamination, the completed series were stored at -21°C until sectioning was finished. The slides were stored at -80°C until the RNAscope Fluorescent Multiplex kit [Advanced Cell Diagnostics (ACD), catalog #320850] protocol commenced.

#### Fluorescent in situ hybridization

The fluorescent in situ hybridization was performed using the RNAscope Fluorescent Multiplex kit (ACD, catalog #320850) in accordance with ACD guidelines for fresh frozen tissues, with minor modifications (Wang et al., 2012) on sections from Glra3-Cre.HTB and sensory stimulated C57BL/6J mice. In brief, as performed previously (Freitag et al., 2021), the slides to be used were taken from -80°C and immediately fixated in 4% FA (Histolab) for 15 min at RT before being washed in autoclaved 1× PBS for 2 min. The tissues were thereafter dehydrated in a stepwise increase of EtOH concentration; 3 min in 50%, 3 min in 70%, and 2× 5 min in 100% (Merck KGaA). The slides were placed at RT for 5 min to dry, whereafter a hydrophobic barrier was made around the chosen sections (three sections/mouse), using an ImmEdge pen (Vector Laboratories). The sections were incubated in protease IV for 30–40 min at RT, followed by  $3 \times 5$  min washing in autoclaved  $1 \times$  PBS. The sections were incubated in target probes (for specifics see Table 1) 1:50 in probe diluent (ACD, catalog #300041) for 2 h at 40°C in a hybridization oven (HybEZ II Oven, ACD). The following amplification steps were performed at 40°C in the hybridization oven, and the sections were washed 2× 2 min in RT washing buffer between each amplification step: AMP 1-FL for 30 min, AMP 2-FL for 15 min, AMP 3-FL for 30 min, and AMP 4-FL for 15 min. The coloring step using AMP 4-FL was performed to enable the combination with the viral fluorescence. Lastly, the slides were washed 2× 2 min in washing buffer before 30 s incubations in DAPI and mounting in Anti-Fade Fluorescence Mounting Medium (Abcam). The slides were covered with glass slides (Menzel-Gläser) and were left at 4°C to dry. The slides were stored at this temperature until imaging.

#### Image acquisition and quantification

Images of immunohistochemistry treated sections were acquired using a wide-field Olympus BX61WI fluorescence microscope (Olympus) with a 10× objective, for which the brightness and contrast were optimized for each channel during image acquisition and quantification. The RNAscope treated sections were acquired with wide-field 20× magnification with an Olympus BX61WI fluorescence microscope (Olympus) or an Axio Imager.Z2 (ZEISS), where each channel was set to be automatically optimized for each image, but had to be further optimized during image analysis. Here, the optimal intensity and contrast was set for one image (reference image) and the settings of the other images were set to match the reference image. The images were manually quantified using the Fiji (ImageJ 1.52f) Cell Counter plug-in.

*Immunohistochemistry spinal cord.* All *Glra3*-Cre.tdTomato (2 females, *n* sections/mouse: 3) or *Glra3*-Cre.mCherry (2 females and 2 males, *n* sections/mouse: 3–5) mice with DAPI overlap were quantified depending on layer location (IB4, outer lamina II; PKCγ, inner lamina II) and marker protein (NEUN) coexpression.

Immunohistochemistry retrograde rabies tracing, spinal cord. Glra3-Cre(+) mice: A DAPI cell with overlap of helper virus GFP and rabies virus mCherry was considered a starter cell, and a DAPI cell with only mCherry overlap was considered a presynaptic traced cell. The coexpression of starter and traced cells was quantified for NEUN and PAX2 (5 females, 5 males, *n* section/mouse/assay: 2–11). *Glra3*-Cre(-) mice: The overlap of helper virus GFP and rabies virus mCherry with DAPI overlap was quantified (3 females, 3 males, every sixth section analyzed).

*Immunohistochemistry retrograde rabies tracing, DRG.* The overlap of traced mCherry DAPI+ cells with NF200, TRKA, CGRP, IB4, TH, and SST were quantified (NF200: 2 females, 2 males, *n* sections/mice: 2–5; TRKA: 2 females, 2 males, *n* section/mice: 1–8; CGRP: 1 female, 2 males, *n* sections/mice: 2–5; TH: 4 females, 2 males, *n* sections/mice: 1–7; SST: 2 females, 1 male, *n* sections/mice: 3–5).

Brain scanning for mCherry(+) traced cells in Glra3-Cre(+) and Glra3-Cre(-) mice. Whole-brain section images were acquired in the mCherry (500 ms) and wide-field black and white (15% light source intensity, 5 ms) channels of every fifth section, using tiles (ZEISS) to scan for mCherry(+) traced cells (Glra3-Cre(+): 5 females, 5 males; Glra3-Cre(-): 3 females, 3 males).

*RNAscope, Glra3-Cre.HTB.* All *Glra3-Cre.HTB* cells with DAPI overlap were considered cells and one read of the targeted probe could be visualized as one dot. A *Glra3-Cre.HTB* cell was considered to be expressing the targeted gene (*Glra3, Vglut2,* or *Viaat*) if the overlapping #dots  $\geq$ 3 (3 females and 2 males, *n* sections/mouse: 2–4). One section from the *Glra3/Viaat* assay was excluded due to weak signal from both probes.

*RNAscope, retrograde rabies tracing DRG.* DAPI cell was considered expressing the targeted gene (*mCherry, Nppb, Mrgpra3, Mrgprd, Trpv1, Trpm8*) if the #dots  $\geq$ 3 (*Nppb:* 1 female and 1 male, *n* sections/mice:4–6; *Mrgprd* and *Mrgpra3:* 1 female and 1 male, *n* sections/mice:4–6, *Trpv1* and *Trpm8:* 2 females and 1 male, *n* sections/mice:2–6).

RNAscope, fos expression in Glra3 expressing cells following sensory stimulation. The experimenter was blinded to the treatment received by the mouse and the Vglut2/Viaat probes, so no randomization was needed in the quantification. A DAPI cell was considered to express the targeted gene (Glra3, fos, and Vglut2 or Viaat) if the #dots  $\geq$ 3 and #dots  $\geq$ 5 for fos (three mice/stimulus, *n* sections/mouse: 3). One section from the scratch analysis was excluded due to poor tissue quality. To obtain a high resolution, two images of each dorsal horn were acquired and later merged together using Adobe Photoshop 22.3 to a composited representative image of the dorsal horn. The result is presented as percentage ± SEM.

#### Electrophysiology

For patch-clamp recordings, spinal cord transverse slices were made from Glra3-Cre;tdTomato mice (13 females, 11 males, 4-35 weeks old) according to a previously described protocol (Freitag et al., 2019). For root stimulations, the spinal cord was cut at a 60° angle and the slice thickness was increased to 400 µm in order to get transverse slices with attached dorsal roots. After incubation, the slice was transferred to a recording chamber, where Glra3-Cre;tdTomato neurons were visualized via a fluorescent LED light source (CoolLED system) on a Prime BSI Express Scientific sCMOS camera (Teledyne Photometrics) through 60× or 10× water-immersion objectives [LUMPlan FI, 0.90 numerical aperture (NA), Olympus]. Borosilicate glass capillaries (GC150F-10 Harvard Apparatus) were used to pull patch electrodes (6–10 M $\Omega$ ) with a flaming/brown micropipette puller (P-1000, Sutter Instrument). The following is the internal solution of patch pipettes (in mM): 130 K-gluconate, 40 HEPES, 1.02 MgCl<sub>2</sub>, 2.17 MgATP, 0.34 NaGTP, with pH adjusted to 7.2 using 1 M KOH. Liquid junction potential was corrected before each recording. Whole-cell patch-clamp signals were amplified with a MultiClamp 700B amplifier (Molecular Devices), digitalized at 20 kHz with Digidata 1440A (Molecular Devices), low-pass filtered at 10 kHz, and acquired in WinWCP software (Dr. J. Dempster, University of Strathclyde).

When the whole-cell configuration was achieved, action potentials (APs) were induced, in the current-clamp mode via current steps from 0 to 150 pA with increments of 10 pA (pulse duration, 500 ms), to monitor the viability and the firing pattern of the patched neuron. The rheobase was determined by using 1 pA increment current steps (pulse duration, 500 ms). The neuron was then held at -60 mV in the voltage-clamp mode. When a stable baseline was achieved in a continuous voltage-clamp recording, 300  $\mu$ M glycine was applied through the perfusion system to the recording chamber to verify the expression of GLRs on the patched neuron. The hyperpolarization was due to the expression of GLRs.

In root stimulation experiments, the dorsal root was identified using the 10× objective and sucked into a suction pipette. The stimulating electric pules were applied via the suction pipette from an A365 Stimulus Isolator (World Precision Instruments). Stimulation pulses with a duration of 0.2 ms were used for activation of the dorsal root, while in some cases 0.5 ms pulse durations were used to activate the C-fiber. The transduction velocities of different afferent fibers were used to determine monosynaptic inputs (Pan et al., 2019), which were further confirmed by none failure responses with consistent onset latencies, where patched cells responded to a minimum of 10 consecutive root stimulations at 1 Hz and the latency variation was <1 ms (Pinto et al., 2008; Pan et al., 2019). Data analyses were done by Clampfit 10.3 (Molecular Devices), Mini Analysis (Synaptosoft), and GraphPad Prism (GraphPad Software). No neurons were excluded in the postanalysis.

#### Cell filling

Neurobiotin Tracer (Vector Laboratories) was added into the intracellular solution (4 mg/ml) and diffused into the target Glra3-Cre;tdTomato cells during the patch-clamp recording. The diffusion of Neurobiotin was further assisted by injecting depolarizing current pulses (0.2-0.5 nA; duration, 150 ms) into the cell at 2 Hz for 10-15 min. After the filling, the patch pipette was carefully detached from the cell and removed from the recording chamber. The excessive Neurobiotin in the tissue was removed by perfusing the slice for at least 15 more min after the removal of the pipette. The slice was then transported into an Eppendorf tube and fixed in 4% FA (Histolab) overnight at 4°C. Fixed slices were washed with 1× PBS (Fisher BioReagents) 4x 10 min before the staining. Slices were stained for PKCy using the same procedure described in previous immunohistochemistry section. Additionally, streptavidin Alexa Flour 488 conjugate (Invitrogen) was added to the primary antibody staining solution with 1:1,000 dilution ratio for Neurobiotin staining. The mounted slice was imaged using a ZEISS LSM700 confocal microscope (ZEISS) with 10× and 20× objectives. The morphology of a filled neuron was reconstructed using the Simple Neurite Tracer plug-in in the NIH ImageJ software (National Institutes of Health).

## *Basal behavioral observation after chemogenetic activation or inhibition of Glra3-Cre(+) neurons*

Glra3-Cre(+) mice (Glra3-Cre.hM3Dq and Glra3-Cre.mCherry: 7+8 mice, 7 females and 8 males; Glra3-Cre.hM4Di and Glra3-Cre.mCherry: 8+8 mice, 11 females, 5 males) unilaterally injected in L5 with AAV8.hsyn-DIO-hM3D(Gq)-mCherry, AAV8.hsyn-DIO-hM4D(Gi)-mCherry, or AAV8.hsyn-DIO-mCherry were acclimatized to a plastic cylinder arena (diameter, 19 cm; height, 29 cm; surface area, 283 cm<sup>2</sup>) with a mirror to obtain a 360° view for 20 min. The mice were injected intraperitoneally with 0.1 mg/kg of freshly prepared clozapine *N*-oxide (CNO; AK Scientific, 0.02 mg/ml dissolved in 0.02% DMSO in sterile saline). The basal behavior of the mice following CNO administration was recorded for 30 min (for Glra3-Cre.hM3Dq recordings) or 60 min (for Glra3-Cre.hM4Di recordings). The duration and frequency of targeted behaviors were analyzed for the total recording time. The same experimenter scored all the behavior recordings and was blinded for the viral vectors used during the experiments. The licking/



Figure 1. Glra3-Cre;tdTomato neurons are predominantly located in laminae III–IV and the adult Glra3-Cre population consists of a major excitatory and a minor inhibitory population. **A**, Overlap of spinal lumbar Glra3-Cre;tdTomato cells (magenta) and neuronal marker NEUN (yellow). Yellow dotted circles display examples of tdTomato(+)NEUN(+) cells. **B**, **B'**, Location of tdTomato(+) cells (magenta) in IB4(+) outer lamina II (white), PKCγ(+) inner lamina II (yellow), laminae III–IV, laminae V–VI, and ventral laminae defined from The Spinal Cord atlas

biting of the ipsilateral paw were scored as one behavior, for which the episodes were scored when contact between the paw and face could be clearly visualized. The guarding and stomping behaviors were also scored. Guarding was defined as the time the mouse spent sitting still with its paw in the air. Stomping was interpreted as a mouse rapidly lifting and lowering the hindpaw while being either still or in movement. No mice were excluded from the analysis

#### Injections of saline or pruritogens

Two days prior to the stimulus recording, the right calves of the mice were shaved and cleaned with sterile saline. Adult Glra3-Cre(+) mice injected with AAV8.hsyn-DIO-hM4D(Gi)-mCherry or control AAV8.hsyn-DIO-mCherry were injected with 0.1 mg/kg freshly prepared CNO (AK Scientific, 0.02 mg/ml dissolved in 0.02% DMSO in sterile saline) and thereafter returned to their respective home cages. After 30 min, the mice were placed in a plastic cylinder arena with a mirror to obtain a 360° view for 10 min to acclimatize to the setup. The mice were subsequently injected subcutaneously in the dorsolateral calf with either 10 µl of saline (8 + 8 mice; 9 females, 7 males), 20 µg compound 48/80 (Sigma-Aldrich, catalog #c2313, dissolved in sterile saline; 8+8 mice; 8 females, 8 males), or 10 mM chloroquine phosphate (Sigma-Aldrich, catalog #PHR1258, dissolved in sterile saline, 8+8 mice; 9 females, 7 males). The mice were returned to the plastic cylinder area and recorded for 30 min. Licking of the calf is indicative of pain, while biting demonstrates itch (LaMotte et al., 2011). However, since we had difficulties separating these behaviors while scoring, the total duration and frequency of licking/biting toward the injected calf was scored as one behavior. These episodes were scored when contact between the calf and face could be clearly visualized. No mice were excluded from the analysis.

#### Randall-Selitto test

Two days prior to the experiment, a plastic cylinder (Model 84, IITC Life Science) was placed in each home cage to acclimatize the mice to the setup. Adult Glra3-Cre(+) mice (7 + 7 mice; 7 females, 7 males) injected with either AAV8.hsyn-DIO-hM4D(Gi)-mCherry or AAV8.hsyn-DIOmCherry between L1/L2 were intraperitoneally administered 0.1 mg/kg freshly prepared CNO (AK Scientific, 0.02 mg/ml dissolved in 0.02% DMSO in sterile saline) and thereafter returned to their respective home cages. Ten minutes later, the mice were allowed to enter the plastic cylinder and were placed in the Randall-Selitto setup (Analgesy-meter, UGO Basile) for ~30 min. When 40 min had passed since the CNO injection, the mechanical threshold (g), at which pressure the mouse retracted its tail, was measured twice per mouse at different locations on the tail with at least 5 min between the measurements. One female and one male injected with AAV8.hsyn-DIO-hM4D(Gi)-mCherry were excluded from the analysis due to lack of mCherry expression in the post hoc verification step.

#### Hargreaves test

Adult *Glra3*-Cre(+) mice (8 + 8 mice; 11 females, 5 males) injected with AAV8.hsyn-DIO-hM4D(Gi)-mCherry or control AAV8.hsyn-DIO-mCherry were initially acclimatized for 60 min in the Hargreaves setup (transparent acrylic glass chambers on glass floor). Baseline thermal sensitivity was measured by directing the Hargreaves heat source (IITC Life Science), guided by a light pointer, to the plantar surface of the right hindpaw, for which the time from turning on the thermal source until the mouse withdrew/flinched its paw was noted. The cutoff time was

set to 20 s to avoid tissue damage, and the withdrawal time was measured twice with at least 5 min intervals in between each measurement. After completed measurements, the mice were injected intraperitoneally with 0.1 mg/kg freshly prepared CNO (AK Scientific, 0.02 mg/ml dissolved in 0.02% DMSO in sterile saline) and placed back into the Hargreaves setup. Forty minutes after the CNO administration, the withdrawal time measurement was repeated. No mice were excluded from the analysis.

#### Acetone drop test

Adult *Glra3*-Cre(+) mice (8 + 8 mice; 8 females, 8 males) injected with either AAV8.hsyn-DIO-hM4D(Gi)-mCherry or AAV8.hsyn-DIOmCherry were allowed 60 min acclimatization to the gridded surface. Forty minutes before the first measurement, the mice were injected intraperitoneally with 0.1 mg/kg freshly prepared CNO (AK Scientific, 0.02 mg/ml dissolved in 0.02% DMSO in sterile saline), and returned to the setup. The mice were subjected to a drop of acetone solution (9:1 acetone in water, Labscan) on the plantar surface of the right hindpaw, where the total duration of sensory aversive behaviors, including lifting, flinching, and licking/biting of the paw, was recorded. The stimulation was performed twice with at least 5 min intervals in between each application of the acetone solution. No mice were excluded from the analysis.

#### Sensory stimulation for fos detection

Pruritic stimulation of urethane-anesthetized mice. To detect activation of Glra3-expressing cells following sensory stimulation, adult C57BL/6J mice (10-14 weeks old, 3 mice/stimulus, 15 mice in total) were initially anesthetized with 2 g/kg urethane (Sigma-Aldrich, catalog #U2500, 125 mg/ml in sterile saline) through intraperitoneal injection to minimize neuronal activity caused by prurito- and nocifensive behavior. To prevent eye damage and dehydration, Oftagel (Santen Oy) was applied to eyes, and the mouse was injected subcutaneously with 0.5 ml saline. To maintain body temperature, a glove filled with body temperature water, which was continuously replaced to sustain temperature, was placed next to the mouse. When the mouse had been fully anesthetized for 10 min, the mouse was subjected to the stimulus. For pruritic stimulations, the mice were injected subcutaneously into the right dorsolateral calf either with 10 µl saline (1 female and 2 males) or a pruritic substance: 20 µg compound 48/80 (Sigma-Aldrich, catalog #c2313, dissolved in sterile saline, 1 female and 2 males) or 20 mM chloroquine (Sigma-Aldrich, catalog #PHR1258, dissolved in sterile saline, 1 female and 2 males).

Noxious mechanical stimulation of urethane-anesthetized mice. The mouse was either subjected to pinching (1 female and 2 males) or scratching (2 females and 1 male) of the skin on the right dorsolateral calf. The pinching was performed  $5 \times$  for 5 s using tweezers, with 5 s resting periods in between each pinching episode. The scratching was conducted for 30 s with 2 Hz and ~300 mN (30.6 g), using an artificial mouse claw in scratch position. Forty minutes after application of the stimulus, the mouse was injected intraperitoneally with 0.05 ml ketamine (Ketalar, 10 mg/ml, Pfizer) and 0.05 ml medetomidine (Domitor, 1 mg/ml, Orion Pharma), followed by perfusion and tissue preparation for RNAscope, as described above.

Hargreaves stimulation for fos detection in awake mice. Adult C57BL/6J mice (2 females and 1 male, 11–17 weeks old) were subjected

~

(Anderson et al., 2009). Yellow dotted circles represent examples of tdTomato(+)PKCy(+) cells. *C*, Scatter bar plot of the occurrence of tdTomato(+)NEUN(+) and tdTomato(+) cells in different spinal areas (2 females, *n* images: NEUN: 10; 2 females, *n* images: PKCy/IB4: 13). *D*, Schematic illustration of AAVDJ.Ef1a-DIO-HTB lumbar 5/lumbar 6 (L5/L6) microinjection into *Glra3*-Cre(+) micre. *E*, *F'*, Overlap of *Glra3* (magenta) and *Vglut2* (white) in adult *Glra3*-Cre.HTB neurons (cyan). Yellow dotted circles indicate *Glra3*(+)*Vglut2*(+), magenta dotted circles denote *Glra3*(+)*Vglut2*(-), and white circles represent *Glra3*(-)*Vglut2*(+) in *Glra3*-Cre.HTB(+) cells. *F*, Scatter bar plot of percentages of *Glra3*-Cre.HTB(+) neurons expressing analyzed genes when targeting *Vglut2* (2 males, *n* sections: 6, images: 12; *G*, *G'*) *Glra3*-Cre.HTB neurons' expression of *Glra3* (magenta) and *Viaat* (white). Yellow dotted circles indicate *Glra3*(+)*Viaat*(-), white dotted circles represent *Glra3*(-)*Vglut2*(+), and blue dotted circles show *Glra3*(-)*Vglut2*(-) in *Glra3*-Cre.HTB(+) cells. *H*, Scatter bar plot displaying percentages of *Glra3*-Cre.HTB(+) neurons expressing analyzed genes when targeting *Viaat* (3 females, *n* sections: 7, images: 15). Scale bars: *A*, *B'*, *E*, *G*, 100 µm; *B*, 150 µm; enlargement in *A*, *E'*, *G'*, 50 µm; enlargement in *B*, 75 µm. The observational dots in the scatter bar plots (*C*, *F*, *H*) represent a unilateral part of the spinal cord and the different dot colors signify different mice. Results are presented as mean  $\pm$  SEM.

8 • J. Neurosci., May 8, 2024 • 44(19):e1585232024



**Figure 2.** *Glra3-Cre;tdTomato* neurons respond to glycine and the populations display a heterogeneous firing pattern. **A**, Patch-clamp recordings of spinal *Glra3-Cre;tdTomato* neurons (magenta). A schematic patch pipette is indicated with a white arrowhead. Scale bar: 50 μm. The image on the right represents a recording of AP firing (above) upon stimulation with a depolarizing current for a duration of 500 ms (below). **B**, Pie chart of the distribution of different AP firing patterns (8 females, 7 males, *n* cells: 69). **B**', Representative recording of each firing pattern. The scale bar applies to all five traces. **C**, Representative recordings of the hyperpolarizing current induced by glycine (300 μM, *n* cells: 13, above) and blockage by strychnine (10 μM, *n* cells: 6, below). The scale bar applies to both traces. **D**, A Neurobiotin filled neuron in a mouse spinal cord slice. Magenta(+) cells are *Glra3-Cre;tdTomato* neurons, PKCγ staining is presented in white, blue is DAPI staining (scale bar, 50 μm). The zoomed in image shows the Neurobiotin filled neuron stained with Alexa Fluor 488 streptavidin conjugate (in green; scale bar, 20 μm). **E**, Morphological and locational reconstruction of all Neurobiotin filled neurons (*n* cells: 13; scale bar, 100 μm). Laminae are defined from The Spinal Cord atlas (Anderson et al., 2009).

to the same Hargreaves protocol as described above for baseline measurements. After completed stimulation, 40 min were allowed to pass until the mouse was injected intraperitoneally with 0.7–0.8 ml ketamine (Ketalar, 10 mg/ml, Pfizer) and medetomidine (Domitor, 1 mg/ml, Orion Pharma; 1:1), followed by perfusion and tissue preparation for RNAscope, as described above. Same mice but separate sections have been used in a manuscript under revision. No mice were excluded from the analysis.

#### Experimental design and statistical analyses

All behavioral testing was performed a minimum of 2-4 weeks after viral injection to allow sufficient expression of viral vector genes. Glra3-Cre.hM3Dq mice were only included in one basal behavioral analysis/mouse, except for 2 (Glra3-Cre.hM3Dq) + 3 (Glra3-Cre.mCherry) mice that also were subjected to an initial analysis (one CNO injection; data not shown) a few weeks prior to establish an optimal CNO concentration. Glra3-Cre.hM4Di mice were included in maximum four behavioral tests (including basal recording) with a minimum of 1 week between the tests. The basal recording was conducted first and the following tests were not conducted in a specific order. Glra3-Cre.mCherry mice were included in maximum four behavioral tests (including basal recording) with a minimum of 1 week between the tests. The tests were not conducted in a specific order. The mice were returned to their home cages after each completed behavioral test. No mice were excluded from the behavioral analyses presented. No randomization was used. Mice were arbitrary assigned to different treatments (e.g., injections of viral vectors) based on sex. All the behavior experiments were conducted by the same female experimenter, who was blinded to viral vectors (control vs chemogenetic). In the acetone and Randall-Selitto tests, an additional female experimenter was conducting the experiment (also blinded to the viral vector injected), so no randomization was needed or possible. Reporter expression was validated and documented in all mice after chemogenetic behavioral testing to ensure presence of DREADD (designer receptors exclusively activated by designer drugs) or control vector at the correct spinal segments. The experimental groups were matched to the best extent in terms of sex and littermates. In the sensory stimulation tests to examine fos, the mice were arbitrary assigned to the different stimuli, but we ensured that both sexes were used in the testing.

The number of mice per behavioral and in situ experiment was not based on any statistical calculations prior to the experiments. Sample sizes are in line with similar studies in the field (Bourane et al., 2015; Foster et al., 2015; Häring et al., 2018). All data were analyzed in GraphPad Prism (version 9 or 10). The normal distribution of the mean data per mouse was analyzed using the Shapiro-Wilk normality test ( $\alpha = 0.05$ ). To compare mean values, we performed either a twotailed Student's t test or Mann-Whitney U test. In the basal hM3Dq experiment, for which the mean value of the control mCherry groups was zero for stomping and guarding behaviors, a chi-square test was performed to compare the mean values between these groups. In order to compare the mean values between multiple parameters (viral vector and pre/post CNO injection) in the Hargreaves test and to compare the differences in the number of the targeted cells following saline, compound 48/80, and chloroquine injections, a one-way ANOVA with Šídák's multiple-comparisons test was used. The results are presented as mean ± SEM.

### Results

# *Glra3-Cre;tdTomato* neurons are predominantly located in laminae III–IV and the adult *Glra3*-Cre population consists of a major excitatory and a minor inhibitory population

First, immunohistochemistry was used to examine the anatomical location and molecular characteristics of the spinal *Glra3*-Cre population using the *tdTomato* reporter line (Fig. 1*A*–*C*). Immunostaining for the neuronal marker NEUN (Fig. 1*A*) showed that almost all tdTomato(+) cells were neurons (98.7 ± 0.2%, 1,637/1,659). The neurons were most frequently found in the dorsal horn (dorsal horn: laminae I–VI, 89.1 ± 2.3%, 1,528/1,713; ventral horn: laminae VII–X, 10.9 ± 2.3%, 185/1,713), especially in laminae III–IV (44.2 ± 2.1%, 753/1,713) and laminae V–VI (23.4 ± 1.6%, 405/1,713). Smaller tdTomato(+) populations were found in lamina I (4.8 ± 0.6%, 78/1,713), the outer lamina II defined by IB4 staining (Todd, 2017; 4.7 ± 0.7%, 80/1,713), and the inner lamina II defined by PKCγ (Polgár et al., 1999; Peirs et al., 2014; 12.1 ± 1.6%, 212/1,713), in which

52.4  $\pm$  5.2% (117/212) of the cells were tdTomato(+)PKC $\gamma$ (+) (Fig. 1*B*,*B*"). Collectively, the *Glra3*-Cre;*tdTomato* neurons were located throughout the spinal cord (Fig. 1*C*) and were most commonly found in laminae III–IV.

Single-cell RNA sequencing (scRNAseq) has identified Glra3 in both excitatory SCGLU10 and Glut9 and in inhibitory Gaba8-9 spinal dorsal horn neuronal clusters among others (Häring et al., 2018; Zeisel et al., 2018). To further examine the molecular characteristics of the Glra3-Cre population and to address adult Glra3-Cre expression, fluorescent in situ hybridization using the RNAscope approach (Wang et al., 2012) was performed. The said method targeted Glra3, the excitatory marker Vglut2 (Vesicular glutamate transporter 2, Slc17a6), and the inhibitory marker Viaat (Vesicular inhibitory amino acid transporter, Slc32a1) in adult AAVDJ.Ef1a-DIO-HTB labeled Glra3-Cre(+) neurons (Fig. 1D-H). HTB is a histone-tagged protein that was used due to its ability to be detected following the RNAscope protocol. Glra3 was expressed by  $74.8 \pm 1.8\%$  (436/571) of the Glra3-Cre.HTB(+) cells in the analysis also targeting Vglut2 and by  $71.7 \pm 4.3\%$  (235/342) of the *Glra3*-Cre.HTB(+) cells in the analysis also targeting Viaat. These findings indicated that the mouse line and Cre-dependent virus mark the Glra3(+) population (Fig. 1E-H). In the Vglut2-examining assay (Fig. 1E,E'), Vglut2(+) and Glra3(+)Vglut2(+) were found in 74.5 ± 2.8%



**Figure 3.** mCherry and chemogenetic viral vector fluorescent genes are not expressed in *Glra3*-Cre(—) wild-type injected mice. Low mCherry fluorescence detection, but no positive cells, could be visualized in close proximity to the L5/L6 injection site of AAV8.hSyn-DIO-mCherry (control virus, 2 females and 1 male; *A*), AAV8.hSyn-DIO-hM3D(Gq)-mCherry (1 female and 2 males; *B*), or AAV8.hSyn-DIO-hM4D(Gi)-mCherry (2 females and 1 male; *C*) injected mice, demonstrating the Cre-dependent specificity of the viral vectors. Scale bar, 150 μm.



**Figure 4.** Adult *Glra3*-Cre(+) neurons are mainly located in laminae III–IV and selective chemogenetic activation induces spontaneous behaviors indicative of a role in nociception and pruriception. *A*, Expression of NEUN (yellow) in *Glra3*-Cre.mCherry (magenta) lumbar spinal cord. Yellow dotted circles represent mCherry(+)NEUN(+) overlap and magenta dotted circles specify mCherry(+)NEUN(-) cells. *B*, *B'*, mCherry(+) colocalization with outer lamina II marker IB4 (white), inner lamina II marker PKCy (yellow), and its expression in laminae III–IV, laminae V–VI, and ventral laminae defined from The Spinal Cord atlas (Anderson et al., 2009). The white dotted circles show mCherry(+) expression in the IB4 band and magenta dotted circles indicate mCherry(+) PKCy(-) cells in the PKCy band. mCherry(+)PKCy(+) cells are not shown in this image. *C*, Scatter bar plot of percentages of mCherry(+)NEUN(+) and laminae layer localization of

Table 2. Membrane and firing properties of Glra3-Cre:tdTomato neurons

Firing pattern	Tonic ( <i>n</i> = 36)	Delayed $(n = 9)$	Phasic ( $n = 12$ )	Irregular ( $n = 7$ )	Single ( $n = 5$ )	Total ( $n = 69$ )
Resting membrane potential (mV)	$-59.37 \pm 1.54$	$-72.33^{a} \pm 3.15$	$-56.33 \pm 2.78$	$-58.14 \pm 1.83$	$-52.40 \pm 3.17$	-59.91 ± 1.22
Input resistance (MΩ)	1,010.6 ± 119.1	732.78 ± 123.53	796.33 ± 119.4	718.71 ± 150	649.60 ± 110.31	$879.43 \pm 70.08$
Capacitance (pF)	$56.79 \pm 7.12$	$79.22 \pm 7.38$	$48.42\pm6.84$	$51.71 \pm 7.54$	$26.40 \pm 6.23$	$55.07 \pm 4.34$
Rheobase (pA)	$21.24 \pm 2.82$	$23.33 \pm 3.51$	$19.00 \pm 4.55$	$20.43 \pm 2.89$	$41.40 \pm 12.82$	$22.56 \pm 2.03$
AP threshold (mV)	$-31.38 \pm 1.55$	$-30.84 \pm 2.73$	$-28.34 \pm 2.88$	$-36.69 \pm 1.65$	$-25.14 \pm 6.51$	$-30.94 \pm 1.12$
AP rising time (ms)	$1.08\pm0.12$	$1.35\pm0.08$	$1.98\pm0.35$	$1.39\pm0.12$	$1.27\pm0.32$	$1.34\pm0.10$
AP peak (mV)	$21.43\pm2.69$	$28.43 \pm 2.77$	$20.80\pm5.15$	$17.16\pm5.16$	$19.59\pm7.68$	$21.71 \pm 1.85$

<sup>a</sup>Delayed AP group showed lower resting membrane potential compared with all the other groups in two-tailed one-way ANOVA followed by Turkey's multiple-comparisons test.

(437/571) and 70.6  $\pm$  2.8% (318/517) of the *Glra3*-Cre.HTB(+) population, respectively (Fig. 1F). Meanwhile, *Viaat*(+) was found in 34.4  $\pm$  3.3% (116/342) and *Glra3*(+)*Viaat*(+) in 28.0  $\pm$  3.75% (89/342) of the *Glra3*-Cre.HTB(+) neurons (Fig. 1*G*,*H*). These results suggest that the adult spinal *Glra3*-Cre population consists of *Glra3*-expressing neurons found in a major *Vglut2*(+) excitatory population and a smaller *Viaat*(+) inhibitory population.

# *Glra3-Cre;tdTomato* neurons respond to glycine and the populations display a heterogeneous firing pattern

Patch-clamp recordings were used to examine electrophysiological properties of *Glra3*-Cre(+) neurons. The recorded *Glra3*-Cre; tdTomato neurons had an average resting membrane potential of  $-59.9 \pm 1.2$  mV, input resistance of  $879 \pm 70.1$  MΩ, and membrane capacitance of 55.1 ± 4.3 pF (Table 2). All recorded neurons fired APs upon electrical stimulation of 500 ms duration and increments of 10 pA (Fig. 2A). Moreover, the APs comprised five different firing patterns (Fig. 2B,B'), with 52% of APs being tonic (36/69), 17% phasic (12/69), 7% single (5/69), 13% delayed (9/69), and 10% irregular (7/69; Fig. 2B,B'; Table 2). These firing patterns resemble previously identified categories of mouse dorsal horn neurons in terms of AP patterns (Hu and Gereau, 2003, 2011; Heinke et al., 2004). The tdTomato(+) neurons had an average rheobase of 22.4  $\pm$  2.8 pA, an AP threshold of  $-30.9 \pm$ 1.1 mV, and a peak AP of  $21.7 \pm 1.8$  mV. Inter-group comparison showed that only neurons with delayed AP patterns had lower resting membrane potentials. No differences were observed in any other measured electrophysiological properties among neurons in the five AP pattern categories (Table 2). Collectively, the Glra3-Cre populations constitute five categories of neurons according to their firing patterns, with homogenous intrinsic membrane properties. The presence of functional glycine receptors on the recorded neurons was determined by applying glycine to the recording chamber in a voltage-clamp mode, where cells were held at -60 mV. All glycine applied Glra3-Cre;tdTomato neurons showed hyperpolarizing currents (an average of -34.8 ± 5.7 pA), and the glycine-induced current was completely blocked by the glycine receptor antagonist strychnine (Fig. 2C).

Two studies have described that GLRA3 is present in the superficial laminae of the dorsal horn (Harvey et al., 2004;

Werynska et al., 2021), while a third study demonstrated that GLRA3 immunoreactivity is also present in the ventral horn (Wang et al., 2018). The latter study is more consistent with our observations as the Glra3-Cre(+) populations were localized in both the dorsal and ventral laminae (Fig. 1A-C), which is also in agreement with mRNA expression of Glra3 (Ceder et al., 2023). To investigate the dendritic localization of Glra3-Cre(+) neurons, we performed cell fillings (Fig. 2D, E). Neurobiotin was used to fill the neurons and the morphology was revealed by staining the filled neuron with Alexa Fluor 488 streptavidin conjugate (Fig. 2D). Dendritic morphologies and locations are showed in Figure 2E. The dendritic tree of each filled neurons appeared to be local and without long projecting dendrites. All neurons showed vertical alignment, where the dendritic arbors projected predominantly in a dorsal-ventral direction.

### Adult *Glra3*-Cre(+) neurons are mainly located in laminae III–IV, and selective chemogenetic activation induces spontaneous behaviors indicative of a role in nociception and pruriception

After the analysis of Glra3-Cre;tdTomato neurons, we further investigated the neuronal profile and anatomical location of adult Glra3-Cre(+) cells. Theoretically, the tdTomato reporter line marks both developmental and adult Glra3-Cre-expressing cells. Therefore, to label the adult population exclusively, reporter virus AAV8.hSyn-DIO-mCherry was unilaterally microinjected into the lumbar 5/lumbar 6 (L5/L6) spinal segments (abbreviated Glra3-Cre.mCherry). First, the specificity of the reporter, and the DREADD viral vectors used for the subsequent sensory behavioral analyses, were investigated by examining mCherry expression in Glra3-Cre(-) control mice. No fluorescent cells were detected (Fig. 3); thus the virally induced gene expression in subsequent analyses was Cre-dependent. The histological analysis (Fig. 4A-C) was conducted in the same manner as in the Glra3-Cre;tdTomato analysis, showing that 89.2 ± 3.9% (1,807/ 2,099) of the mCherry(+) cells coexpressed NEUN (Fig. 4A,C). In consistency with the tdTomato analysis, the mCherry(+) population was predominantly located in the dorsal horn (86.4 ± 3.2%, 1,279/1,524), with a minor subpopulation in the ventral

<sup>←</sup> 

mCherry(+) neurons (2 females, 2 males, *n* sections: NEUN: 31; PKCY/IB4: 16). Scale bars: *A*, *B*, 100 µm; zoomed images, 50 µm. The observational dots in the scatter bar plots represent a unilateral part of the spinal cord, and different dot colors signify different mice. Results are presented as mean  $\pm$  SEM. *D*–*F*, Spontaneous behaviors, including licking/biting, stomping, and guarding of the corresponding dermatome (hindpaw/leg), were observed in *Glra3*-Cre.hM3Dq mice (7 + 8 mice; 7 females, 8 males) after 0.1 mg/kg intraperitoneal administration of CNO. *D*, Chemogenetic activation of the *Glra3*-Cre populations increased total duration and frequency of licking/biting of the ipsilateral hindpaw compared with *Glra3*-Cre.mCherry mice in the 30 min time window post-CNO injection (duration, *p* = 0.0006; frequency, *p* = 0.0002). *E*, Spontaneous stomping behavior was observed in *Glra3*-Cre.hM3Dq mice following CNO injection, which was not seen in *Glra3*-Cre.mCherry mice (duration and frequency, *p* < 0.0001). *F*, *Glra3*-Cre.hM3Dq mice displayed guarding behaviors not observed in control mice. Both guarding duration and frequency were affected by *Glra3*-Cre population activation (*p* < 0.0001). Results are presented as mean  $\pm$  SEM. Mann–Whitney *U* test was performed in *D* and chi-square test in *E* and *F* to compare the group means. \*\**p* < 0.0001.



**Figure 5.** Chemogenetic silencing of *Glra3*-Cre(+) neurons decreases histaminergic and chloroquine-induced itch. *A*, Dendritic and cytosolic expression of mCherry (magenta) after AAV8.hSyn-DIO-mCherry microinjection (top). Dendritic and cytosolic localization of hM4D(Gi)-mCherry (yellow) after microinjection of AAV8.hSyn-DIO-hM4D(Gi)-mCherry (bottom). *B*, Intraperitoneal administration of CN0 (0.1 mg/kg) did not induce spontaneous licking/biting of the affected dermatome in the 0–30 or 30–60 min intervals postinjection (duration: 0–30 min, p = 0.7463; 30–60 min, p = 0.4589; frequency: 0–30 min, p = 0.4109; 30–60 min, p = 0.3945, 8 mice/group; 11 females, 5 males). *C*, Neither licking duration nor frequency were affected by saline administration (10 µl, duration, p = 0.7923; frequency, p = 0.9405, 8 mice/group; 9 females, 7 males). *D*, Silencing *Glra3*-Cre(+) neurons attenuated the licking/biting duration and frequency following compound 48/80 (20 µg, 10 µl) injection (duration, p = 0.0037; frequency, p = 0.0017; frequency, p = 0.0028, 8 mice/group; 9 females, 7 males). *E*, *Glra3*-Cre.hM4Di mice displayed lower licking/biting duration and frequency following chloroquine (10 mM, 10 µl) injection (duration, p = 0.0117; frequency, p = 0.0084, 8 mice/group; 9 females, 7 males). *F*, Silencing of sacral

horn (15.0 ± 4.5%, 245/1,524; Fig. 4*B*,*C*). In the dorsal horn, the mCherry(+) cells were mainly restricted to laminae III–IV (40.1 ± 4.2%, 590/1,524), followed by lamina I (14.2 ± 2.7%, 179/1,524), laminae V–VI (11.6 ± 2.0%, 222/1,524), the PKC $\gamma$ (+) inner lamina II (11.1 ± 1.2%, 166/1,524) in which 21.3 ± 5.4% (41/166) of the mCherry(+) neurons were PKC $\gamma$ (+), and the IB4(+) outer lamina II (9.4 ± 1.4%, 122/1,524; Fig. 4*B*,*C*).

Activation of spinal GLYT2 neurons decreases pain and itch behaviors (Foster et al., 2015), and the anatomical location of the Glra3-Cre(+) neurons showed herein indicates a sensory role of Glra3(+) neurons. To investigate this, Glra3-Cre(+) mice were unilaterally injected into L5/L6 with AAV8.hSyn-DIO-hM3D(Gq)-mCherry (abbreviated *Glra3*-Cre.hM3Dq) and the behavioral phenotype was compared with Glra3-Cre.mCherry mice (control; Fig. 3D-F). The mice were administered CNO to selectively activate the Glra3-Cre populations. After CNO administration, Glra3-Cre.hM3Dq mice displayed a higher duration and frequency of licking/biting of the ipsilateral hindpaw compared with control mice (Fig. 4D). In mice, licking of the hindpaw is associated with pain, while biting is a sign of itch (LaMotte et al., 2011). Therefore, our phenotype indicated both a nociceptive and a pruriceptive role for the Glra3-Cre populations. Additionally, activation of the Glra3-Cre.hM3Dq population resulted in stomping (Casarrubea et al., 2019) and guarding (Wang and Wang, 2003; Mogil and Crager, 2004), which were not observed in control mice (Fig.  $4E_{r}F$ ). These behaviors further indicated nociceptive/pruriceptive-related roles of these populations. Collectively, activation of the lumbar spinal Glra3-Cre populations results in nocifensive and pruritofensive behaviors.

# Chemogenetic silencing of the *Glra3*-Cre populations decreases chloroquine- and compound 48/80-induced itch

Since selective chemogenetic activation of *Glra3*-Cre(+) neurons induced spontaneous behaviors indicative of a role in pain/itch transmission, we sought to decipher the involvement of this population in different sensory modalities. For this purpose, adult Glra3-Cre(+) mice were unilaterally injected with AAV8hSyn-DIO-hM4D(Gi)-mCherry in L5/L6 (abbreviated Glra3-Cre.hM4Di) to enable selective silencing while sensory behaviors were monitored. The results were compared with control virusinjected Glra3-Cre.mCherry mice (Fig. 5A). First, the basal behavioral phenotype was investigated following CNO administration. Selective silencing of Glra3-Cre(+) neurons did not affect spontaneous licking/biting behaviors in duration nor frequency during the 0-30 and 30-60 min intervals after CNO administration (Fig. 5B). Stomping and guarding behaviors were not observed when silencing the Glra3-Cre populations (data not shown).

In consistency with the Bourane et al. (2015) study, the mice were subjected to sensory testing 40 min after CNO administration. The pruriceptive role of the spinal lumbar *Glra3*-Cre population was examined in hairy skin, for which mice were administered either control saline, compound 48/80, or

chloroquine solution (chemical itch) subcutaneously into the calf (Fig. 5C-E). Compound 48/80 activates sensory neurons both directly via MRGPRA1 (Schemann et al., 2012; Azimi et al., 2016, 2017) and indirectly as a mast cell degranulator by binding MRGPRB2 (Azimi et al., 2016), resulting in the release of pro-inflammatory molecules and pruritogens, including histamine and serotonin (Gupta and Harvima, 2018). Chloroquine activates primary afferents expressing MRGPRA3 (Liu et al., 2009). Saline evoked no differences in the duration or frequency of licking/biting of the injected area (Fig. 5C), showing that the Glra3-Cre populations do not convey sensory information associated with the injection itself. When administering compound 48/80, both the duration and frequency of licking/biting of the affected area were decreased following Glra3-Cre(+) silencing (Fig. 5D). For chloroquine administration, the same results were observed as with compound 48/80 injection (Fig. 5E).

The role of the Glra3-Cre populations in noxious mechanical transmission was examined using the Randall-Selitto test. To target the tail dermatome, AAV8-hSyn-DIO-hM4D(Gi)-mCherry or the control virus was injected in the sacral 2 (S2) segment (Bennett et al., 1999). The mechanical threshold for Glra3-Cre.hM4Di mice did not differ compared with Glra3-Cre.mCherry mice (Fig. 5F). To investigate if the Glra3-Cre populations are involved in thermal transmission, we performed the Hargreaves and acetone drop tests (Fig. 5G,H). Withdrawal response times, within groups, induced by heat stimulation of the ipsilateral hindpaw were not affected when comparing preand post-CNO administration in Glra3-Cre.mCherry or Glra3-Cre.hM4Di mice (Fig. 5G). When further comparing the withdrawal response times between the Glra3-Cre.mCherry and Glra3-Cre.hM4Di mice following CNO administration, no differences were observed (Fig. 5G). Application of a drop of acetone solution to the plantar surface of the ipsilateral hindpaw did not alter sensory responses, including flinching, withdrawal, or licking/biting of the paw (Fig. 5H). In conclusion, the Glra3-Cre populations have a pro-pruritic role in compound 48/80- and chloroquine-evoked itch, while not involved in acute noxious mechanical or thermal transmission.

# Spinal neurons activated by compound 48/80 or chloroquine coexpress *Glra3*

Based on the behavioral observations, we wanted to molecularly verify the proposed sensory role of spinal Glra3(+) neurons and subsequently relate it to the Vglut2(+) and Viaat(+) spinal Glra3-Cre subpopulations. To do so, sensory stimulations in anesthetized and awake C57BL/6J mice were performed, followed by RNAscope (Wang et al., 2012) analyses of *fos* (Sheng and Greenberg, 1990), *Glra3*, and *Vglut2* or *Viaat* in the L4/L6 dorsal spinal cord. The mice were subjected to one of six possible stimuli: a subcutaneous injection of saline, compound 48/80, or chloroquine subcutaneously in the right dorsolateral calf, a noxious mechanical stimulus (pinch or scratching) of the right dorsolateral calf, or thermal (Hargreaves) stimulation of the right hindpaw (Fig. 6A-L; for separate channels see Figs. 7, 8).

<sup>~</sup> 

*Glra3*-Cre(+) neurons did not affect the mechanical threshold in the tail (p = 0.5110, 7 mice/group, 7 females, 7 males). *G*, *H*, *Glra3*-Cre(+) neurons are not involved in thermal transmission. *G*, Thermal stimulation (Hargreaves) of the ipsilateral hindpaw did neither affect the withdrawal latency in post-CN0 administrated *Glra3*-Cre.hM4Di mice compared with *Glra3*-Cre.mCherry mice, nor the response pre- and postadministration of CN0 in *Glra3*-Cre.hM4Di mice (*Glra3*-Cre.mCherry pre vs post CN0: p = 0.9981; *Glra3*-Cre.hM4Di pre vs post CN0: p = 0.9659; *Glra3*-Cre.mCherry vs *Glra3*-Cre.hM4Di post CN0: p = 0.5326, 8 mice/group; 11 females, 5 males). *H*, Application of acetone solution (9:1 in water) did not affect the aversive response when silencing *Glra3*-Cre(+) neurons (p = 0.1145, 8 mice/group; 8 females, 8 males). Scale bar: *A*, 100 µm. All results are presented as mean ± SEM. To compare the mean values, Mann–Whitney *U* test was performed in *C* (saline duration) and *E*, unpaired two-tailed Student's *t* test was performed in *C* (saline frequency), *D*, *F*, and *H*. In *G*, a one-way ANOVA with Šídák's multiple-comparisons test was used. \*p < 0.05, \*\*p < 0.01.



**Figure 6.** Spinal neurons activated by compound 48/80 or chloroquine coexpress *Glra3*. C57BL/6J mice were subjected to different sensory stimuli, whereafter the *Glra3* (magenta) and *fos* (cyan) coexpressional patterns were investigated (DAPI (dark blue)). *A–B'*, Saline (10 µl; 1 female, 2 males); *C–D'*, compound 48/80 (20 µg, 10 µl; 1 female, 2 males); *E–F'*, chloroquine (20 mM, 10 µl; 1 female, 2 males); *G–H'*, scratch [30 s, ~300 mN (30.6 g); 2 females, 1 male]; and *I–J'*, pinch (5 times for 5 s; 1 female, 2 males) in urethane-anesthetized mice (2 g/kg).

Scratching of the calf is not a natural behavior of mice; however, this stimulation was conducted in this area to enable comparison with the other stimuli. To prevent transcriptional influence from pain- and itch-responsive behaviors, we performed all stimulations under urethane anesthesia, except for the Hargreaves test that was performed on awake freely moving mice. All stimuli, except saline, were found to have a higher number of fos(+) cells on the ipsilateral side compared with the contralateral side: saline contralateral  $47 \pm 5$  (847) and ipsilateral  $48 \pm 2$  (862); compound 48/80 contralateral  $43 \pm 3$  (779) and ipsilateral  $75 \pm 5$  (1,347); chloroquine contralateral  $24 \pm 5$  (426) and ipsilateral  $41 \pm 3$ (745); artificial scratching contralateral  $36 \pm 3$  (606) and ipsilateral 52  $\pm$  4 (889); pinch contralateral 36  $\pm$  3 (573) and ipsilateral 52 ± 12 (834); and noxious heat (Hargreaves) contralateral 21 ± 3 (378) and ipsilateral  $27 \pm 2$  (485) (Fig. 6M). Fos(+) Glra3(+)-expressing cells were found to be greater in number on the ipsilateral dorsal horn than those on the contralateral dorsal horn for both compound 48/80 and chloroquine (Fig. 6N). The average number of fos(+)Glra3(+) cells in the ipsilateral dorsal horn after injection with compound 48/80 was higher than the average number of fos(+)Glra3(+) cells after saline injection, which was not observed for chloroquine administration (Fig. 6N). Of fos(+) cells, more than half of compound 48/80and chloroquine-activated cells expressed Glra3 [compound 48/80, 59% (795/1,347); chloroquine, 67% (502/745); saline, 52% (449/862); scratch, 50% (442/889); pinch, 49% (218/443); Hargreaves, 47% (230/486)]. No difference in the number of fos(+)Glra3(+) expressing cells could be detected for scratch, pinch, or Hargreaves (comparing the ipsi- and contralateral sides; Fig. 6O). Altogether, these findings verify that Glra3(+) neurons are involved in the communication of compound 48/ 80- and chloroquine-induced itch and that these neurons are not involved in acute mechanical or thermal transmission. Since Glra3 is found in both excitatory and inhibitory neuronal populations (Häring et al., 2018; Zeisel et al., 2018), we further investigated the sensory modality activation of these fos(+)Glra3(+) subpopulations after injections with saline, compound 48/80, or chloroquine, focusing on the ipsilateral dorsal horn (Fig.  $9A-H^{22}$ ). All three stimuli led to the expression of fos in both Glra3(+)Vglut2(+) and Glra3(+)Viaat(+) populations (Fig. 9B). Taken together, the transcriptional analysis shows that Glra3 is expressed in compound 48/80- and chloroquineactivated neurons, suggesting a role in transmission of these two sensory stimuli. Moreover, the sensory modality activated fos(+)Glra3(+) cells can be found in subpopulations expressing the excitatory marker Vglut2(+) or the inhibitory marker Viaat(+).

# Lumbar *Glra3*-Cre(+) neurons receive monosynaptic input from excitatory and inhibitory local spinal neurons

After identifying a pro-pruritic role for *Glra3*-Cre(+) neurons via behavioral experiments and coexpression of Glra3 in compound 48/80- and chloroquine-activated fos(+) cells, we investigated the connectivity of lumbar Glra3-Cre(+) neurons. Retrograde viral tracing and dorsal root stimulation were used to deduce the mono- and polysynaptic neurons targeting the Glra3-Cre populations. To enable analysis of the monosynaptic connectivity, we performed a two-step viral injection procedure. First, the helper virus AAV8.Syn-flex-TVA-oG-GFP was injected, enabling Glra3-Cre(+) host cell entry and subsequent retrograde monosynaptic propagation of the secondly injected EnvA pseudotyped mCherry rabies virus. In the spinal cord of control Glra3-Cre(-) mice, no helper GFP(+)mCherry(-) nor starter GFP(+) mCherry(+) cells were detected. Two mCherry(+) cells were found in the cervical division [1 cell in the ipsilateral dorsal horn and 1 mCherry(+) cell in the contralateral ventral horn (one in each mouse); Fig. 10A,B]. In the brain, no traced mCherry(+) cells were detected in control mice. In the lumbar DRG, 51 mCherry(+) cells (43 ipsilateral, 8 contralateral) were found in two mice (43 ipsilateral and 6 contralateral in one mouse and 2 contralateral in a second mouse), verifying the Cre-dependent robustness and reliability of this tracing system.

In the spinal cords of *Glra3*-Cre(+) mice, 94 starter GFP(+) mCherry(+) cells were localized in the lumbar enlargement (Fig. 10*C*",*D*). Furthermore, 526 traced mCherry(+) cells were found in the ipsilateral lumbar enlargement, and in four out of five mice, 16 traced cells were found in the contralateral lumbar spinal cord. None of these mice had any starter GFP(+) mCherry(+) cells located on the contralateral side (Fig. 10*C*,*D*). Thus, it is possible that the *Glra3*-Cre populations receive some input from the contralateral side in addition to abundant ipsilateral lorsal horn of the cervical division, while none were detected in either thoracic or sacral divisions (Fig. 10*C*–*C*"), indicating that the *Glra3*-Cre populations receive mainly local spinal input.

To molecularly examine the starter and traced cells, we investigated the colocalizations with NEUN and the inhibitory marker PAX2 (Larsson, 2017). Starter cells overlapped 44% (17/39), whereas 79% (191/241) of the traced cells colocalized with NEUN (Fig. 11*A*,*B*). 30.9% (17/55) of the starter cells, and 35.4% (101/285) of the traced cells overlapped with PAX2 (Fig. 11*C*,*D*), which, in consistency with the RNAscope findings, further indicates that the *Glra3*-Cre population comprises an inhibitory subpopulation. In the dorsal–ventral axis, the mCherry(+) cells were mainly located in the dorsal horn (laminae I–VI;

*K*–*L'*, Hargreaves (stimulated 3 times; 2 females, 1 male) in awake and freely moving mice. *A*–*L*, Representative images of the contralateral and ipsilateral (stimulated side) dorsal horns for each stimulus, with dose ups. *Fos*(+)*Glra3*(+) cells are depicted by a dotted magenta circle. Scale bars: *A*–*L*, 100 µm; zoomed in *A*, *B*, *E*–*J*, 20 µm; zoomed in *C*, *D*, *K*, *L*, 50 µm. To obtain high resolution, two images of each dorsal horn were acquired and later merged together, to a composited representative image of the dorsal horn, using Adobe Photoshop 22.3. *A'*–*L'*, Schematic illustrations of the *fos*(+) and *fos*(+)*Glra3*(+)cells, where each cell is illustrated by a circle; *fos*(+) in cyan and *fos*(+)*Glra3*(+) in magenta (*n* sections; saline, 16; compound 48/80, 17; chloroquine, 17; artificial scratching, 16; pinch, 17; and Hargreaves, 18). *M*, Scatter bar plot of the average number of *fos*(+) cells per dorsal horn for each stimulus on the contralateral (white bar) and ipsilateral (gray bar) side. *N*, *O*, Scatter bar plot of the average number of *fos*(+) cells per dorsal horn for each stimulus on the contralateral (gray bar) side. Results are presented as mean ± SEM. Individual mice are marked with magenta, yellow, and cyan in *M*–*O* to display the spread between sections and mice. Paired two-tailed Student's *t* tests were performed in *M*–*O*, and a one-way ANOVA with Šídák's multiple-comparisons test to check for differences between saline, compound 48/80, and chloroquine injections. *M*, Contralateral versus ipsilateral: saline, *p* = 0.8372; compound 48/80, *p* < 0.0001; chloroquine, *p* < 0.0001; artificial scratching, *p* < 0.0001; pinch, *p* = 0.0014; and noxious heat (Hargreaves), *p* = 0.0218. *N*, The number of *fos*(+)*Glra3*(+) cells was higher on the ipsilateral side when injections, only compound 48/80 injection resulted in a higher number of *fos*(+)*Glra3*(+) cells (*p* < 0.0001). *O*, No differences in the number of *fos*(+)*Glra3*(+) neurons were detected for sc



**Figure 7.** Expression of *GIra3* and *fos* in the contralateral L5/L6 dorsal horn following calf or paw stimulation in anesthetized or awake freely moving mice. *A*–*F*, The expression of *GIra3* (magenta) in the contralateral L5/L6 dorsal horn following sensory stimulation. *A'*–*F'*, Expression of *fos* (cyan) in the contralateral L5/L6 dorsal horn after sensory stimulation. *A*, *A'*, Saline (10 µl, 1 female, 2 males) injection in urethane (2 g/kg) anesthetized mice. *B*, *B'*, Compound 48/80 (20 µg, 10 µl, 1 female, 2 males) injection in urethane-anesthetized mice. *C*, *C'*, Chloroquine (20 mM, 10 µl, 1 female, 2 males) injection in urethane-anesthetized mice. *D*, *D'*, Scratching [30 s with 2 Hz and ~300 mN (30.6 g), 2 females, 1 male] in urethane-anesthetized mice. *E*, *E'*, Pinching (5 times for 5 s, 1 female, 2 males) in urethane-anesthetized mice. *S*, *E'*, Pinching (5 times, 2 females and 1 male) in freely moving awake mice. Scale bar: 50 µm. To obtain high resolution, two images of each dorsal horn were acquired and later merged together to a composited representative image of the dorsal horn using Adobe Photoshop 22.3.

Fig. 11*E*,*F*), suggesting that the spinal input to the *Glra3*-Cre populations predominately constitutes of sensory-related transmission. A smaller subpopulation of mCherry(+) cells was observed in the ventral horn (laminae VII–IX) and lamina X (Fig. 11*E*,*F*), with

the former suggesting that the *Glra3*-Cre populations potentially receive input from motor-related spinal neurons.

# Lumbar *Glra3*-Cre(+) neurons receive monosynaptic input from several brain areas

In the brain, a total of 89 traced mCherry(+) cells were detected in seven out of 10 Glra3-Cre(+) mice. One mouse had a traced cell in the ipsilateral and two mice had traced cells in the contralateral motor cortices (M1, M2; n cell = 9). In a third mouse, traced cells were located in the ipsilateral somatosensory cortex, barrel field (S1BF; n cells = 2) area (Fig. 12A). Three mice had mCherry(+) cells in the contralateral p1 reticular formation (p1Rt; n cells = 7; Fig. 12B) and in the red nucleus magnocellular part/red nucleus parvicellular part (RPC/RMC; *n* cells = 16 cells; Fig. 12*C*). In addition, traced cells were detected in the ipsilateral and contralateral pontine reticular nucleus, either in the oral (PnO; *n* cells = 10) or caudal part (PnC; *n* cells = 7; Fig. 12D), and bilaterally in the gigantocellular vestibular nucleus (Gi; ncells = 8; Fig. 12*E*). This demonstrates that the lumbar Glra3-Cre populations receive monosynaptic input from several brain areas. For details regarding brain area localization of the traced mCherry(+) cells in the individual mice, see Table 3.

# The spinal *Glra3*-Cre populations receive monosynaptic information from multiple subgroups of primary afferents

Mono- and presynaptic traced mCherry(+) cells were detected in lumbar DRG of *Glra3*-Cre(+) mice, indicating that these spinal populations receive peripheral monosynaptic input. The traced cells were mainly found ipsilateral, but a few mCherry(+) cells were also detected in contralateral lumbar DRG in two out of six mice (*n* cells = 20). In *Glra3*-Cre(+) mice, traced cells were found in one ipsilateral thoracic DRG in two separate mice (n cells = 47). In one of these mice, and in a third mouse, mCherry(+) cells (*n* cells = 20) were found in one contralateral thoracic DRG. As mentioned above, mCherry(+) cells were observed in the contralateral DRG in two Glra3-Cre(-) mice, implying that the contralateral mCherry(+) cells found in the Glra3-Cre(+) mice may be false positives. To identify the Glra3-Cre(+) contacting primary afferents, we examined the overlap with the markers NF200, TRKA, CGRP, IB4, TH, Mrgprd, Mrgpra3, SST, Nppb, Trpv1, and Trpm8 (Averill et al., 1995; Patapoutian et al., 2003; Li et al., 2011; Usoskin et al., 2015; Albisetti et al., 2017; Kupari and Ernfors, 2023; Fig. 13A-N, for separate channels, see Fig. 14). Of the ipsilateral lumbar DRG mCherry(+) cells, 28.4% (591/2,079) belonged to the neurofilament heavy myelinated NF200(+) group (Fig. 13A,L), which is present in A $\delta$ - and A $\alpha$ / $\beta$ -fibers (Basbaum et al., 2009; Meltzer et al., 2021). CGRP is a pro-pruritic and noxious neuropeptide (McCoy et al., 2012; Rogoz et al., 2014), which is highly coexpressed with noxious receptor TRKA (Woolf et al., 1994; Averill et al., 1995; McCoy et al., 2012; Barker et al., 2020), and both genes have little overlap with IB4-binding fibers (Averill et al., 1995; McCoy et al., 2012; Usoskin et al., 2015). In total, 34.9% (687/1,988) of mCherry(+) cells overlapped with the TRKA(+) population (Fig. 14B,L) and 20.3% (213/1,049) with CGRP(+) (Fig. 13C,L). Furthermore, 26.6% (391/1,472) of the mCherry(+) cells overlapped with small unmyelinated nonpeptidergic neuronal binding marker IB4 (Fig. 14D,L), and 9.2% (179/ 1,951) with TH (Fig. 13E,L), which is expressed in low-threshold mechanosensory C-fibers (Li et al., 2011). In contrast, 79.5% (591/743) of the NF200(+), 57.1% (687/1,203) of TRKA(+), 58.0% (213/367) of CGRP(+), 57.9% (391/675) of IB4-binding, and 29.9% (179/598) of TH(+) neurons were mCherry(+)



**Figure 8.** The expression of *Glra3*, sensory modality-induced *fos* cells, and *Vglut2* or *Viaat* in L5/L6 after dorsolateral calf or paw mechanical or heat stimulation in anesthetized or awake freely moving mice. *A*–*E*<sup>*w*</sup>, Expressional view (*A*–*F*) of *Glra3* (', magenta), *fos* (", cyan), and *Vglut2* or *Viaat* ("', white) in the L5/L6 ipsilateral dorsal horn after sensory stimulation of the dorsolateral calf in urethane (2 g/kg) anesthetized mice [scratch: 30 s with 2 Hz and ~300 mN (30.6 g), 2 females, 1 male; pinch: 5 times for 5 s; 1 female, 2 males]. *a*–*e*<sup>*w*</sup>, Zoomed in view of the respective marker genes after stimulation. *F*–*F*<sup>*w*</sup>, Expressional view (*F*) of *Glra3* (*F*, magenta), *fos* (*F*, cyan), and *Vglut2* or *Viaat* (*F*<sup>*w*</sup>, white) in the L5/L6 ipsilateral dorsal horn after noxious heat stimulation of the hindpaw (stimulated 3 times with 20 s cutoff time; 2 females, 1 male) in awake freely moving mice. *f*–*f*<sup>*w*</sup>, Zoomed in view of the respective marker genes after noxious heat stimulation. Magenta dotted circles show *fos*(+)*Glra3*(+), light pink indicates *fos*(+)*Viaat*(+), and dark magenta shows *fos*(+)*Glra3*(+)*Vglut2*(+). Scale bars: *A*–*F*, 50 µm; *a*–*f*<sup>*w*</sup>, 20 pm. To obtain high resolution, two images of each dorsal horn were acquired and later merged together to a composited representative image of the dorsal horn using Adobe Photoshop 22.3.



**Figure 9.** Compound 48/80- and chloroquine-induced *fos* cells expressing *Glra3* are both excitatory and inhibitory. Expression of *fos*, *Glra3*, and *Vglut2* or *Viaat*, and the ipsilateral L5/L6 dorsal horn spatial location of cells expressing these genes (3 mice of mixed sex/stimulation, *n* sections/mice: 2–4), following control saline (10 μl, *n* sections: 9), compound 48/80 (20 μg, 10 μl, *n* sections: *Vglut2*: 8; *Viaat*: 9), or chloroquine (20 mM, 10 μl, *n* sections: *Vglut2*: 9; *Viaat*: 9) calf injections in urethane (2 g/kg) anesthetized mice. **A**, Schematic illustration of calf injections. **B**, The coexpression of *Vglut2* or *Viaat* in saline, compound 48/80-, and chloroquine-activated *fos*(+)*Glra3*(+) cells. Both excitatory *Glra3*(+)*Vglut2*(+) and inhibitory *Glra3*(+)*Viaat*(+) neurons are activated following saline, compound 48/80, and chloroquine administration. Saline-activated *fos*(+)*Glra3*(+) population showed 40.9 ± 3.6% (94/231) coexpression with *Vglut2* and

(Fig. 13*M*). Not all primary sensory afferents are equally susceptible to retrograde tracing by rabies virus (Albisetti et al., 2017); however, the overlap of the traced mCherry(+) neurons with all markers indicates that the spinal *Glra3*-Cre populations receive monosynaptic peripheral information from several fiber subtypes.

To obtain a more detailed view of the peripheral input to lumbar Glra3-Cre(+) neurons, we targeted markers for receptor and neurotransmitter DRG subtypes (Kupari and Ernfors, 2023; Fig. 13F-M). Three pruriceptive molecular clusters have previously been identified, namely, NP1, NP2, and NP3. Mrgprd is expressed in the NP1 cluster, Mrgpra3 in the NP2, and SST/ Nppb in the NP3 cluster (Usoskin et al., 2015), where Sst has little colocalization with IB4 (Usoskin et al., 2015; Stantcheva et al., 2016). Mrgprd was detected in 37.5% (147/392) (Fig. 13F,L), Mrgpra3 in 17.6% (99/392; Fig. 14G,L), SST in 21.4% (265/ 1,239; Fig. 13H,L), and Nppb in 20.3% (72/354; Fig. 13I,L) of the traced mCherry(+) cells. Strikingly, mCherry was detected in a large portion of the pruriceptive subclusters: 46.5% (147/ 316) of Mrgprd(+), 69.7% (69/99) of Mrgpra3(+), 66.9% (265/ 394) of SST(+), and 40.9% (72/176) of Nppb(+) neurons (Fig. 14M), supporting the behavioral finding of the Glra3-Cre populations facilitating itch-related transmission. Lastly, the expressions of the temperature-sensitive channels Trpv1 and Trpm8 were investigated. Trpv1 is activated by capsaicin and noxious temperatures ( $\geq$ 42°C), while *Trpm8* is activated by menthol and cooling temperatures (<26-28°C; Patapoutian et al., 2003). Herein, 13.5% (53/392) and 2.3% (9/392) of the mCherry(+) cells expressed Trpv1 or Trpm8, respectively (Fig. 13J-L). In contrast, 13.2% (53/403) of the Trpv1(+) and 14.3% (9/63) of the Trpm8(+) populations expressed mCherry (Fig. 13M). The low overlap of Trpv1 in traced neurons is consistent with both the low coexpression of Glra3 in Hargreaves-induced fos(+) cells and the lack of phenotype of DREADD-mediated inactivation of Glra3-Cre(+) neurons in the same test.

To further investigate and validate that *Glra3*-Cre(+) neurons receive peripheral monosynaptic input, patch-clamp recordings were conducted on *Glra3*-Cre(+) [reporter tdTomato(+) and viral mCherry(+)] neurons in combination with dorsal root stimulation (Fig. 13*N*). The data revealed that the *Glra3*-Cre populations receive monosynaptic inputs from all afferent fiber subtypes. Half of the recorded neurons (16/32) received monosynaptic inputs from at least two afferent fibers, among which almost one-third (5/16) formed monosynaptic connections with all three fiber subtypes. Furthermore, the majority of synaptic inputs was delivered via  $A\alpha/\beta$  fibers (41%) or C-fibers (40%), while only 19% was transmitted by A $\delta$  fibers (Fig. 13*O*). Collectively, these results confirmed that *Glra3*-Cre(+) neurons receive monosynaptic information from multiple afferent fiber subtypes, including myelinated and itch-associated neurons, suggesting that the *Glra3*-Cre populations form complex monosynaptic connections with primary afferents.

### Discussion

Herein, we report that the Glra3-Cre line labels excitatory and inhibitory primarily dorsal neuronal populations in the spinal cord that express Glra3. These populations respond to glycine and are heterogeneous in terms of AP firing patterns and homogenous in intrinsic membrane properties. Behavioral and expressional analyses revealed that spinal Glra3-Cre populations have a pro-pruritic role in compound 48/80- and chloroquine-evoked itch and no role in the mechanical or thermal responses that have been tested in this study. Analyses using monosynaptic retrograde tracing and dorsal root stimulations demonstrated that lumbar Glra3-Cre populations receive monosynaptic excitatory and inhibitory input from neurons within the lumbar division, several brain areas related to sensory and motor functions, and afferents belonging to the NF200(+), TRKA(+), IB4-binding, and TH(+) subpopulations. Furthermore, CGRP(+) and pruritic markers Mrgprd(+), Mrgpra3(+), SST(+), and Nppb(+) afferent populations were found to synapse on spinal Glra3-Cre(+) neurons. The multitude of sensory modality input to this population was confirmed with dorsal root stimulations. Taken together, the data show that the spinal Glra3-Cre populations communicate compound 48/80 and chloroquine-evoked itch.

The glycinergic system is a fast response inhibitory system important for modulating motor and sensory reflex activity, muscle tone, and respiratory rhythms (Manzke et al., 2010; Cioffi, 2018). The glycinergic system serves a protective role in pain and itch, where activation of glycinergic neurons leads to attenuated pain and itch responses, and ablation causes nociceptive and pruriceptive hypersensitivity (Foster et al., 2015). Blocking spinal glycine receptors decreases the nociceptive counterstimulation effect on persistent itch-mediated spontaneous activity in the spinal cord (Akiyama et al., 2011), implementing the importance of the glycinergic system in sensory regulation. Our chemogenetic activation experiments indicate that the adult spinal Glra3-Cre populations have an acute sensory role as its activation evoked spontaneous sensory behaviors, such as licking/biting, stomping, and guarding of the affected dermatome, whereas silencing decreased compound 48/80- and chloroquine-induced itch, indicative of a pro-pruritic role.

In the retrograde rabies tracing experiment, we investigated overlap of traced neurons with primary afferent subtype markers to deduce the sensory modality input to the spinal *Glra3*-Cre populations. Almost half of the NP1-*Mrgprd*(+) ( $\beta$ -alanine

 $<sup>\</sup>leftarrow$ 

<sup>56.1</sup>  $\pm$  4.4% (124/218) with *Viaat*; compound 48/80 displayed 53.2  $\pm$  4.9% (208/373) and 45.7  $\pm$  3.2% (196/422) coexpression with *Vglut2* and *Viaat*, respectively. Chloroquine-activated *fos*(+) *Glra3*(+) neurons coexpressed both *Vglut2* and *Viaat* in similar proportions: 40.8  $\pm$  4.6% (98/238) and 40.9  $\pm$  3.5% (107/264), respectively. The graph presents data as mean  $\pm$  SEM. *C*–*H*<sup>*m*</sup>, Each panel shows the overview of the expression of the targeted genes with nucleus marker DAPI (dark blue) first, followed by *Glra3*(', magenta), sensory stimulation-induced *fos*('', cyan), and *Vglut2* or *Viaat*(''', white). Magenta dotted circle: *fos*(+)*Glra3*(+) cells; white dotted circle: *fos*(+)*Glra3*(+)*Vglut2*(+) or *fos*(+)*Glra3*(+)*Viaat*(+) cells. The schematic images in ('''') show the spatial localization of the sensory-induced *fos*(+) cells (cyan), *fos*(+)*Glra3*(+) (magenta), and *fos*(+)*Glra3*(+)*Vglut2*(+) (*C'''', E'''', G''''*; purple) or *fos*(+)*Glra3*(+)*Viaat*(+) (*D'''', F'''', H''''*; light pink) cells. *C'''', D''''', Saline* injection resulted in a widespread *fos*(+) cell pattern in the dorsal horn, and overlapping cells with *Glra3*(+) could be found in the whole dorsal horn. Moreover, the saline-activated *fos*(+)*Glra3*(+)*Vglut2*(+) cells (*gr''')* and *Glra3*(+)*Viaat*(+) cells (*F'''')* and *Glra3*(+)*Viaat*(+) cells (*F'''')* were found to be located more to the lateral part of the dorsal horn, while the saline-activated *fos*(+) cells (*gr''')* and *Glra3*(+)*Viaat*(+) cells (*F'''')* were found in the same area. *G'''', H''''*, Chloroquine-activated *fos*(+) cells (*stereet* in similar patterns as observed for compound 48/80, but the chloroquine *fos*(+) cells were fewer in number compared with compound 48/80. *Fos*(+)*Glra3*(+)*Vglut2*(+) cells (*G'''')* were found more dorsolateral, similar to *fos*(+) *Glra3*(+)*Viaat*(+) cells (*H'''')*, which were found mostly dorsolateral but with a higher degree of scattering. Scale bars: *C*-*H*, 100 µm; *C*-*h*, 50 µm. To obtai



**Figure 10.** Starter and traced cells were mainly found in the lumbar division in *Glra3*-Cre(+) mice and only a few cells were detected in *Glra3*-Cre(-) mice. *A*–*A*<sup>'''</sup>, No starter GFP(+) mCherry(+) or traced mCherry(+) cells were detected in the thoracic (*A*'), lumbar (*A*''), or sacral (*A*''') divisions in *Glra3*-Cre(-) mice. Two mCherry(+) cells were found in the cervical (*A*) division in two separate mice, where 1 mCherry(+) cell was found in the contralateral ventral horn and 1 cell in the ipsilateral dorsal horn (3 females, 3 males, every sixth section analyzed). These cells are not depicted in the image. *B*, No starter GFP(+)mCherry(+) or traced mCherry(+) cells were observed at the injection site of *Glra3*-Cre(-) mice. *C*, Starter GFP(+)mCherry(+) and traced mCherry(+) cells were found in the lumbar division (*C*'') and 1 mCherry(+) cell was observed in the distant cervical (*C*), whereas no traced cells were located in the thoracic (*C*) or sacral (*C*''') divisions in *Glra3*-Cre(+) mice. The blue dotted circles represents GFP(+)mCherry(-) cells and the yellow dotted circles show GFP(+)mCherry(+) starter cells. Traced mCherry(+) is not displayed in images. GFP is displayed as cyan and mCherry as magenta (DAPI as yellow). Scale bars: *A*–*A*''', *C*–*C*''', 300 µm; *B*, *D*, 150 µm. For high resolution, images were acquired in 10× and were thereafter merged for representation in Adobe Photoshop 22.3.

receptor; Liu et al., 2012) and NP3-Nppb(+)/Sst(+) (Usoskin et al., 2015; Stantcheva et al., 2016) primary afferents synapse on *Glra3*-Cre(+) neurons. Activation of SST(+) primary afferents evokes pruritofensive behaviors and deletion of *Sst* attenuates

itch evoked by pruritogens, such as compound 48/80 and chloroquine (Huang et al., 2018). Furthermore, SST(+) primary afferent ablation decreases histamine, chloroquine, IL-31- and serotonin-evoked scratching (Stantcheva et al., 2016). Herein,

![](_page_20_Figure_2.jpeg)

**Figure 11.** Lumbar *Glra3*-Cre(+) neurons receive monosynaptic input from excitatory and inhibitory local spinal neurons. *A*, Coexpression of NEUN (yellow) in *Glra3*-Cre starter GFP(+) mCherry(+) and traced mCherry(+) cells. *B*, Pie charts of NEUN overlap in ipsilateral starter *Glra3*-Cre(+) (top chart) and traced cells (bottom chart; 3 females, 2 males, *n* images: 29). *C*, Colocalization of PAX2 (yellow) in *Glra3*-Cre starter GFP(+)mCherry(+) and traced mCherry(+) cells. GFP is displayed as cyan and mCherry as magenta. *D*, Pie charts of coexpression of PAX2 in the starter *Glra3*-Cre(+) (top chart) and traced cells (bottom chart; 3 females, 2 males, *n* images: 31). Scale bars: *A*, *C*, 150 µm; zoomed images, 75 µm. *E*, Schematic illustration of the spatial localization of NEUN(+) and NEUN(-) *Glra3*-Cre starter GFP(+)mCherry(+) and traced mCherry(+) cells in the ipsi- and contralateral spinal lumbar division. *F*, Schematic illustration of *Glra3*-Cre starter GFP(+)mCherry(+) cell localizations and overlap with PAX2 in the ipsi- and contralateral spinal lumbar division. The marker(+) starter cells are shown as cyan dots and the marker(-) starter cells as gray dots, whereas the marker(+) traced cells are depicted as yellow dots and marker(-) traced cells as magenta dots. The schematic image was acquired from Atlas of the Mouse Spinal Cord (Watson and Paxinos, 2009). For starter and traced cells in *Glra3*-Cre(-) mice and the cervical, thoracic and sacral divisions of the spinal cord in *Glra3*-Cre(+) mice, please see Figure 10.

we found that almost 70% of SST(+) primary afferents and chloroquine receptor Mrgpra3(+) primary afferents, found in the NP2 cluster (Liu et al., 2009; Usoskin et al., 2015), synapse on *Glra3*-Cre(+) neurons. TRKA is the receptor of NGFβ, a neurotrophic protein important for hyperalgesia (Woolf et al., 1994; Barker et al., 2020) and CGRP is a neuropeptide with pro-pruritic and noxious functions (McCoy et al., 2012; Rogoz et al., 2014). Ntrk1 (gene encoding TRKA) and Calca (gene encoding CGRP) are highly coexpressed in nonpeptidergic pruriceptive NP2 neurons and in nociceptive peptidergic PEP1-2 neurons. Our retrograde monosynaptic tracing showed that Glra3-Cre(+) neurons receive monosynaptic input from TRKA(+) and CGRP(+) primary afferents. The dorsal root stimulation further confirmed that these populations receive monosynaptic input from C-fibers, collectively implying that spinal *Glra3*-Cre(+) neurons are central for communicating itch.

Transcriptional validation of the behavioral involvement of spinal *Glra3*-Cre(+) neurons in different sensory modalities

confirmed that *Glra3* is largely expressed in compound 48/ 80-evoked *fos*(+) neurons compared with saline-induced *fos*(+) cells. Compared with the contralateral side, chloroquineactivated *fos*(+) cells expressed *Glra3* but this effect could not be separated from the influence of the injection itself. However, the chloroquine-activated cells constitute a smaller population than the saline-activated group (p < 0.0001), which may explain this result. Previous studies have found that itch-inducing compounds activate cells in the superficial dorsal horn (Yao et al., 1992; Doi-Saika et al., 1997; Jinks and Carstens, 2000; Nojima et al., 2003; Nakano et al., 2008; Han et al., 2012; Akiyama et al., 2013; Gatto et al., 2021), which is similar to our findings.

Consistent with the absence of thermal response alterations following *Glra3* deletion/mutation observed by the cited studies (Harvey et al., 2009; Werynska et al., 2021), chemogenetic silencing of *Glra3*-Cre neurons did not alter the withdrawal response in the Hargreaves test. Subsequent histological analysis showed that Hargreaves-activated fos(+) cells did not overlap with *Glra3* 

![](_page_21_Figure_1.jpeg)

Weman et al. • Spinal *Glra3* Cells Signal Itch in Hairy Skin

compared with the contralateral side in naive mice. Moreover, silencing did not affect the response in the acetone drop test, further dismissing involvement of the spinal *Glra3*-Cre(+) neurons in acute thermal transmission. The retrograde rabies tracing revealed that the Glra3-Cre populations receive sparse monosynaptic input from Trpm8(+) primary afferents, while 13.5% of the traced DRG neurons overlapped with Trpv1. TRPV1(+) primary afferents are key mediators in itch transmission (Mishra et al., 2011; Rogoz et al., 2014) and TRPV1-deficient mice show reduced responses to histamine (Imamachi et al., 2009). The *TrpV1(+)* primary afferent input to the lumbar *Glra3*-Cre populations may therefore be related to itch rather than thermal sensation. Silencing of GLYT2 neurons do however regulate both mechanical and thermal transmission (Foster et al., 2015) and activation of GLYT2 neurons has an antihyperalgesic effect on neuropathic-induced mechanical allodynia (Foster et al., 2015). Meanwhile, deletion/mutation of Glra3 does not affect the withdrawal response to mechanical and thermal stimulation following nerve injury (Harvey et al., 2009; Werynska et al., 2021). Chemogenetic silencing of the Glra3-Cre populations did not affect the acute mechanical sensitivity in the Randall-Selitto test and scratch- or pinch-activated fos(+) cells did not express Glra3 in higher occurrence compared with the contralateral side in naive mice. Conclusively, our analyses indicate that the Glra3-Cre(+) neurons may not be the postsynaptic target of the GLYT2 population in regulation of noxious mechanical and thermal transmission. However, since GLRA3 has been connected to inflammatory-induced hypersensitivity (Harvey et al., 2009; Werynska et al., 2021), future investigations targeting the role of Glra3-Cre(+) neurons in inflammatory, neuropathic, thermal, and mechanical allodynia are of interest.

Besides input from itch-related primary afferents, the monosynaptic tracing experiments and dorsal root stimulations revealed that the Glra3-Cre populations receive input from  $A\alpha/\beta$  fibers as partial overlap with NF200(+). As NF200 can be detected in A<sup>β</sup> low-threshold mechanoreceptors (LTMRs), A<sup>β</sup> high-threshold mechanoreceptors (HTMRs), and Aδ-fibers (Djouhri and Lawson, 2004; Nagi et al., 2019; Meltzer et al., 2021), input from these neuronal subpopulations cannot be excluded. Furthermore, the overlap of mCherry(+) cells with TH(+) neurons, which convey low-threshold mechanical information and are possibly associated with pleasant touch (Li et al., 2011), proposes that the lumbar Glra3-Cre populations receive several categories of sensory input. In addition, traced cells were found in the ventral horn (laminae VII-IV), indicating that the Glra3-Cre populations may receive input from spinal motor-related neurons. Additionally, starter, lineage, and virally labeled Glra3-Cre(+) cells were observed in the ventral horn. In line with these observations, we recently showed that Glra3 is detected in the dorsal and ventral horns of the lumbar division (Ceder et al., 2023). Thus, it remains unclear whether sensory-

Figure 12. Lumbar Glra3-Cre(+) neurons receive monosynaptic input from several brain areas. A-D, Schematic illustrations of the mono- and presynaptic traced mCherry(+) cells found in several brain areas [n cells = 89 from 7 out of the 10 mice; 5 females, 5 males; 3 females and 4 males had traced mCherry(+) cells]. The brain areas with more than one mCherry(+) cell or the brain areas with mCherry(+) cells in more than one mouse are shown in the figure. The coloring of the dots represents the different mice and the schematic images were acquired from The Mouse Brain Atlas in Stereotaxic Coordinates (Paxinos and Franklin, 2001). A, Traced mCherry(+) cells in the ipsilateral and contralateral primary and secondary motor cortices (M1, M2; bregma: -0.94-(-)1.22 mm; 2 females) and in the ipsilateral

somatosensory cortex, barrel field [S1BF; bregma: 0.38–(–)1.34 mm; 1 male]. **B**, mCherry(+) cells were observed in the contralateral p1 reticular formation [p1Rt; bregma:-3.08-(-) 3.16 mm; 3 females].  $\boldsymbol{C}$ , The contralateral localization of mCherry(+) cells in the magnocellular and parvicellular parts [RMC and RPC; bregma: -3.08-(-)4.04 mm; 3 females]. D, The ipsilateral and contralateral localization of traced mCherry(+) cells in the oral and caudal part of the pontine reticular nucleus [PnO and PnC; bregma: -4.24-(-)5.23 mm; 2 females, 2 males]. *E*, mCherry(+) cells were bilaterally localized in the gigantocellular vestibular nucleus [Gi; breqma: -5.88-(-)6.97 mm; 2 females, 2 males]. Scale bar, 100 μm.

Image         Image <thimage< th="">         Image         <thi< th=""><th>Sex</th><th>Animal ID</th><th>Bregma</th><th>Brain structure abbreviation</th><th>Brain structure</th><th>Number of cells</th><th>Ipsi/Contra</th></thi<></thimage<>	Sex	Animal ID	Bregma	Brain structure abbreviation	Brain structure	Number of cells	Ipsi/Contra
-8.0         p1R:0im         p1 reticular formation/retionethmold nucleus, parvicellular part         1         Centra           -3.16         p1R         Ret nucleus, magnocellular part/red nucleus, parvicellular part         1         Centra           -3.80         RA         Ret nucleus, magnocellular part/red nucleus, parvicellular part         2         Centra           -3.80         RA         Medial vestibular nucleus nucleus, parvicellular part         2         Centra           -5.88         NVPC         Medial vestibular nucleus nucleus, parvicellular part         2         Centra           -6.80         NVPC         Medial vestibular nucleus nucleus, parvicellular part         3         Centra           -6.81         NVPC         Medial vestibular nucleus nucleus, parvicellular part         3         Centra           -6.81         NVPC         Medial vestibular nucleus, nucleus, parvicellular part         3         Centra           -1.22         MINAC         Pelmary motor cotra         3         Centra           -3.84         Pilkar         Pelmary motor cotra         1         Centra           -3.84         BNRC         Red nucleus, magnocellular part/red nucleus, parvicellular part         1         Centra           -3.84         Pilkar         Seator         Seator	Female	1	-3.08-(-4.04)	RMC	Red nucleus, magnocellular part	5	Contra
-3.16         plR:         pl reticular formation         1         Contra           -3.52         RMCRPC         Reduces, magneelidur parted nucles, parvieliular part         1         Contra           -3.80         IR         Intermodes, magneelidur parted nucles, parvieliular part         1         Contra           -5.80         IVPC         Medial vestibular nucles, magneelidur part         2         Contra           -5.81         MVEPC         Gangancelidur vestibular nucles, magneelidur part         2         Contra           -6.82         Gangancelidur vestibular nucles, magneelidur part         1         Contra           -6.82         MVEPC         Medial vestibular nucles, magneelidur part         1         Contra           -6.84         MVEPC         Reduces, magneelidur part         1         Contra           -7.24         MVIAPC         Promotro cretx-         3         Contra           -3.84         pl reticular formation         2         Contra           -3.84         MCMPC         Reduces, magneelidur part         1         Contra           -3.84         MCMPC         Reduces, magneelidur part         2         Contra           -3.84         PAC         Reduces, magneelidur part         2         Contra <t< td=""><td></td><td></td><td>-3.08</td><td>p1Rt/REth</td><td>p1 reticular formation/retroethmoid nucleus</td><td>1</td><td>Contra</td></t<>			-3.08	p1Rt/REth	p1 reticular formation/retroethmoid nucleus	1	Contra
-5.2         RMCRPC         Red nucles, magnocillair part/red nucles, parvicellular part         1         Contra           -5.80         Ra         Intermediate redinal nucles;         2         Contra           -5.80         Rive         Medial vestibular nucleus, magnocillular part         2         Contra           -6.81         MVePC         Medial vestibular nucleus, magnocillular part         2         Contra           -6.81         MVePC         Medial vestibular nucleus, parvicellular part         2         Contra           -6.92         MVePC         Medial vestibular nucleus, parvicellular part         3         Contra          -6.93         MVePC         Medial vestibular nucleus, parvicellular part         3         Contra           -6.94         M2         Seconsym motor cortex, consym motor cortex         3         Contra           -7.94         M1A         Primary motor cortex/secondary motor cortex         1         Upica           -7.94         M2A         Seconsym motor cortex/secondary motor cortex         1         Upica           -7.94         M2A         Seconsym motor cortex/secondary motor cortex         1         Upica           -7.94         M2A         Seconsym motor cortex         1         Upica         Upica           -7.94 <td></td> <td></td> <td>-3.16</td> <td>p1Rt</td> <td>p1 reticular formation</td> <td>1</td> <td>Contra</td>			-3.16	p1Rt	p1 reticular formation	1	Contra
Female         -3.80         PaR         Paratubal nucleus         1         Contra           -5.80         Bit         Intermediate reinduar nucleus panorellular part         1         Ipsi           -5.83         MVePC         Medial vestibular nucleus panorellular part         1         Contra           -6.84         MVePC         Medial vestibular nucleus panorellular part         1         Contra           -6.84         MI         Medial vestibular nucleus panorellular part         1         Contra           -6.84         MI         Medial vestibular nucleus panorellular part         1         Contra           -6.94         MI         Panore nucleus panorellular part         1         Contra           -1.22         MI/M2         Panore nucleus panorellular part         1         Contra           -3.86         pl.RCRPC         Red nucleus, magnocellular part         1         Contra           -3.40         RMCRPC         Ref nucleus, magnocellular part         1         Contra           -4.44         IPA         Supaoacionnotor preinageducial grap         1         Ipsi, contra           -4.44         RMCRPC         Red nucleus, magnocellular part         1         Contra           -5.40         PA         Panolinary nucleus <td></td> <td></td> <td>-3.52</td> <td>RMC/RPC</td> <td>Red nucleus, magnocellular part/red nucleus, parvicellular part</td> <td>1</td> <td>Contra</td>			-3.52	RMC/RPC	Red nucleus, magnocellular part/red nucleus, parvicellular part	1	Contra
-s.80         Nith         Intermediate incluar inclues         2         Contra           -s.88         MMeNC         Medial vestibular inclues, payricellular part         2         Contra           -6.90         MMeNC         Medial vestibular inclues, payricellular part         2         Contra           -6.90         MMeNC         Medial vestibular inclues, payricellular part         3         Contra           -6.90         MM2         Secondary motor cotex         3         Contra           -1.91         MM2         Secondary motor cotex         3         Contra           -1.91         MM2         Primary motor cotex/secondary motor cortex         3         Contra           -3.08         Pitt         Primary motor cotex/secondary motor cortex         3         Contra           -3.09         MKC         Rel nucleus, magnocellular part         2         Contra           -3.00         MKC         Rel nucleus, magnocellular part         1         Dist           -4.44         Fig         Magnocellular part         2         Contra           -4.44         Fig         Magnocellular part         2         Contra           -5.20         PiC         Poto         Poto         Poto         Poto         Poto			-3.80	PaR	Paratubal nucleus	1	Contra
-5.88         MiMeRC         Medial vestibular nucleus, magnocellular part         1         [pin]           -5.89         MiMeRC         Gigantocellular vestibular nucleus         1         Contra           -6.12         Gi         Gigantocellular vestibular nucleus         3         Contra           -6.04         MiRe         Medial vestibular nucleus         3         Contra           -1.20         MiMeRC         Secondary motor cortex         3         Contra           -1.310         MiMeRC         Reduceus, magnocellular part/red nucleus, parvicellular part         2         Contra           -3.16         MiK/PC         Reduceus, magnocellular part/red nucleus, parvicellular part         2         Contra           -3.40         MiK/PC         Reduceus, magnocellular part         2         Contra           -4.40         IPAG         Lateral periaqueducal gray         1         Upisi           -4.41         PRIP         Reducemental induceus, magnocellular part         1         Contra           -5.20         PRO         Pontore rectolar nucleus, coal part         1         Contra           -5.38         Sufe/Live         Sandersemental periaqueducal gray         1         1         Sandersemental sectolar induceus, magnocellular part           -			-5.80	IRt	Intermediate reticular nucleus	2	Contra
			-5.88	MVeMC	Medial vestibular nucleus, magnocellular part	1	lpsi
Female6.12GiGigantocellular westbalar incleus1ContraFemale-2-6.96MVM1Primary motor cortex3Contra-0.94M2Secondary motor cortex1Ipis1Ipis-1.22M1/M2Primary motor cortex/secondary motor cortex1Ipis-3.16RMC/RPCRef nucleus, magnocellular part/ed nucleus, parvicellular part2Contra-3.16RMC/RPCRef nucleus, magnocellular part/ed nucleus, parvicellular part2Contra-4.04LPAGLPAGRef nucleus, magnocellular part1Ipis-4.04LPAGRef nucleus, magnocellular part1Contra-4.04LPAGRef nucleus, magnocellular part1Contra-4.04PigPrOReticulotegmental nucleus, oral part1Contra-5.20PGPontine recidiar nucleus, and part71 ipis, 1 contra-5.20PGPontine recidiar nucleus, and part1Contra-5.20PGGigantocellular nucleus, and part1Contra-5.20PGGigantocellular nucleus, and part1Ipis-5.20PGGigantocellular nucleus, and part1Ipis-5.20PGGigantocellular nucleus, and part1Ipis-5.20PGGigantocellular nucleus, and part1Ipis-5.21SplveSplanal vestbalar nucleus1Ipis-7.22M2Splanal vestbalar nucleus1 <td< td=""><td></td><td></td><td>-5.88</td><td>MVePC</td><td>Medial vestibular nucleus, parvicellular part</td><td>2</td><td>Contra</td></td<>			-5.88	MVePC	Medial vestibular nucleus, parvicellular part	2	Contra
Female2-6.56MVeMedial vestibular nucleus1ContraFemale2-0.94M1Pirnary motor cortex3Contra-1.24M1/M2Pirnary motor cortex/secondary motor cortex1 psi-1.38piltpile ciclar formation2Contra-3.48piltpile ciclar formation2Contra-3.44RMC/RPCRef nucleus, magnocellular part/ref nucleus, parcicellular part2Contra-3.40RMCRef nucleus, magnocellular part1Ipsi-4.44-4.44M1Meencephilar rectical formation1Contra-4.24PigPn0Reticulotegmental nucleus, oral part1Contra-5.20PnCPontine rectical nucleus, colad part1Contra-5.38SulveSuperior vestibular nucleus, colad part1Contra-5.38SulveSuperior vestibular nucleus1Contra-5.38SulveSuperior vestibular nucleus1Contra-5.38SulveSuperior vestibular nucleus1Ipsi-5.38SulveSuperior vestibular nucleus1Ipsi-5.38SulveSuperior vestibular nucleus1Ipsi-5.38SulveSuperior vestibular nucleus1Ipsi-5.38SulveSuperior vestibular nucleus1Ipsi-5.38SulveSulveSuperior vestibular nucleus1Ipsi-5.38SulveSulveSulve<			-6.12	Gi	Gigantocellular vestibular nucleus	1	Contra
Female     2     -0.94     M1     Primary motor cortex     3     Contra       -0.94     M2     Secondary motor cortex     1     Ipis       -1.22     M1/M2     Primary motor cortex/secondary motor cortex     1     Ipis       -3.16     RMCRPC     Ref nucleus, magnocellular part en uncleus, parvicellular part     2     Contra       -3.16     RMCRPC     Ref nucleus, magnocellular part en uncleus, parvicellular part     2     Contra       -4.04     UPAG     Lateral periaqueductal gray     1     Ipis       -4.04     Su3     Supacoulomotor periaqueductal gray     1     Ipis, contra       -4.04     PIg/Pro     Periadulotegramental nucleus, oral part     7     1pis, contra       -4.04     PIg/Pro     Periadulotegramental nucleus, calad part     2     1pis, 1 contra       -5.20     PO     Parabinary moter cotex/secondular nucleus, and part     1     Contra       -5.38     SuVeV     Superior vestbular nucleus, factal periadulotal rucleus, factal periadulotal rucleus, and part     1     Contra       -5.38     SuVeV     Superior vestbular nucleus, factal periadulotal rucleus, factal periadulotal rucleus, factal vestbular nucleus, factal periadulotal rucleus, factal vestbular nucleus, factal ve			-6.96	MVe	Medial vestibular nucleus	1	Contra
Partial         -0.94         M2         Secondary motor cortex         3         Contra           -1.22         M1/M2         Primary motor cortex/secondary motor cortex         1         Ipit           -3.86         p1Rt         p1 reticular formation         2         Contra           -3.16         MK/RPC         Red nucleus, magnocellular part/red nucleus, parvicellular part         2         Contra           -3.40         MKC         Red nucleus, magnocellular part/red nucleus, parvicellular part         1         Ipit           -4.04         Su3         Suparacolmotor periaqueductal gray         1         Ipis 6. contra           -4.24         mRT         Mesencephalic reticular formation         2         1/16 js 6. contra           -5.20         PRC         Pontine reticular nucleus, ord part         1         Contra           -5.20         PRC         Pontine reticular nucleus, sord part         1         Contra           -5.20         PRC         Superior vestibular nucleus         1         Contra           -5.20         PRC         Superior vestibular nucleus         1         Supsi 3. contra           -5.88         SuVe/LeV         Superior vestibular nucleus         1         Supsi 3. contra           -5.88         SuVe/LeV <td>Female</td> <td>2</td> <td>-0.94</td> <td>M1</td> <td>Primary motor cortex</td> <td>3</td> <td>Contra</td>	Female	2	-0.94	M1	Primary motor cortex	3	Contra
Female         1         1         1         1         1         1           1         -3.08         p1kt         1         <			-0.94	M2	Secondary motor cortex	3	Contra
-3.08         p1th         p1 reficular formation         2         Contra           -3.16         RMC/RPC         Ref nucleus, magnocellular part /ed nucleus, parvicellular part         2         Contra           -3.40         RMC         Ref nucleus, magnocellular part         2         Contra           -4.04         LPAG         Lateral perliaqueductal gray         1         lpsi           -4.04         Su3         Supaccionotrop repriaqueductal gray         1         lpsi           -4.24         PTG/PAD         Reticuloregrainqueductal, oral part         1         Contra           -4.24         PTG/PAD         Reticuloregrainqueductal, oral part         1         Contra           -4.24         PTG/PAD         Reticuloregrainqueductal, oral part         1         Contra           -5.20         PO         Pontine reticular nucleus, oral part         1         Contra           -5.20         PO         Pontine reticular nucleus, oral part         1         Contra           -5.20         PO         Pontine reticular nucleus, oral part         1         Contra           -5.20         PO         Pontine reticular nucleus, oral part         1         Contra           -5.28         SuVe1VeVe         Superior vestibular nucleus         1<			-1.22	M1/M2	Primary motor cortex/secondary motor cortex	1	lpsi
Partial     Partial     RMC/RPC     Red nucleus, magnocellular part/red nucleus, parvicellular part     2     Contra       Partial     Partial     Red nucleus, magnocellular part     2     Contra       Partial     Partial     Red nucleus, magnocellular part     2     Contra       Partial     Partial     Red nucleus, magnocellular part     1     Ipsi       Partial     Partial     Red nucleus, magnocellular part     1     Contra       Partial     Partial     Red nucleus, magnocellular part     1     Contra       Partial     Partial     Partial     Red nucleus, magnocellular part/red nucleus, oral part     1     Contra       Partial     Partial     Partial     Pontine reticular nucleus, oral part     7     1 (psi, 1 contra       Partial     Partial     Pontine reticular nucleus, caudal part     1     Contra       Partial     Partial     Pontine reticular nucleus     Pontine reticular nucleus     1     Contra       Partial     Partial     Superior vestibular nucleus     Pontine reticular partial vestibular nucleus     1     Contra       Partial     Partial     Pontine reticular nucleus     Partial     Pontine     1     Pontine       Partial     Partial     Pontine reticular nucleus     Pontine     1     Dontra			-3.08	p1Rt	p1 reticular formation	2	Contra
Partial         -3.40         RMC         Red nucleus, magnocellular part         2         Contra           -4.04         LPAG         Lateral pertaqueductal gray         1         ipsi           -4.04         Su3         Suppacolomotro pertaqueductal gray         1         ipsi           -4.24         mR1         Mesencephalic reticular formation         1         Contra           -4.24         Plg/PnO         Perturbutant nucleus, orl part         7         1 ipsi, 6 contra           -4.44         -4.48         Plg/PnO         Pontine reticular nucleus, acidad part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, acidad part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, acidad part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, acidad part         7         1 ipsi, 2 contra           -5.20         PnC         Superior vestibular nucleus/Alteral vestibular nucleus         5         2 ipsi, 3 contra           -5.88         SuVe/Ve/Ve         Superior vestibular nucleus         3         1 ipsi, 2 contra           -7.280         Sal         Soldary tora         1 ipsi, 2 contra         1 ipsi			-3.16	RMC/RPC	Red nucleus, magnocellular part/red nucleus, parvicellular part	2	Contra
Percent     -4.04     LPAG     Leteral periaqueductal gray     1     ipsi       -4.04     Su3     Suprocolomotor periaqueductal gray     1     ipsi       -4.24     mRT     Mescncephalic reticular formation     1     Contra       -4.24     mRT     Mescncephalic reticular nucleus, oral part     1     Contra       -4.44     -4.24     PRO     Pontine reticular nucleus, oral part     1     Contra       -5.20     PnO     Pontine reticular nucleus, oral part     1     Contra       -5.20     PO     Pontine reticular nucleus, oral part     1     Contra       -5.86     SuVe     Superior vestibular nucleus     1     Contra       -5.88     SuVe/Ve     Superior vestibular nucleus     1     Ipsi       -5.84     -5.88     SuVe/Ve     Superior vestibular nucleus     1     Ipsi       -6.96     C1     C1 adrenaline cells     1     Ipsi       -7.8     Sol     Sol     Sol     Ipsi     Ipsi       -7.8     Sol     Sol     Sontra     Ipsi     Ipsi       -7.8     Sol     Primary motor cortex     1     Ipsi       -7.8     Sol     Reticular formation     2     Ipsi       -7.8     Sol     Primary motor cor			-3.40	RMC	Red nucleus, magnocellular part	2	Contra
-4.04         Su3         Supracolomotor periaqueductal gray         1         Ipsi           -4.24         PRT         Mescnephalic reticular formation         1         Contra           -4.24         PTQPho1         Reticulotegremental nucleus; or the pons/pontine reticular nucleus, or al part         1         Contra           -4.44         PTQPho1         Pontine reticular nucleus, or al part         7         1 ipsi, 6 contra           -5.20         PrO         Paraolivary nucleus, caudal part         1         Contra           -5.20         PrO         Paraolivary nucleus         1         Contra           -5.88         SuVe/Ve         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.88         SuVe/Ve         Superior vestibular nucleus         1         Ipsi, 3 contra           -6.24         -7.08         Gal         Gigantocellular vestibular nucleus         1         Ipsi           -7.08         Sol         Sol         Soliary trat         1         Ipsi           -7.08         Sol         Soliary trat         1         Ipsi           -7.08         Pal         Pal         Contra         Contra           -3.28         RPC         Red nucleus, gangrocellular part			-4.04	LPAG	Lateral periagueductal gray	1	ipsi
-4.24         mRT         Mesencephalic reticular formation         1         Contra           -4.24         PTg/PhO         Reticuloregemental nucleus or the pors/pontine reticular nucleus, oral part         1         Contra           -4.48-(4.60)         PhO         Pontine reticular nucleus, oral part         2         1 (psi, 6 contra           -5.20         PhC         Pontine reticular nucleus, oral part         1         Contra           -5.20         PhO         Paradivary nucleus         1         Contra           -5.20         PhO         Paradivary nucleus         1         Contra           -5.58         SuVe/         Superior vestibular nucleus         1         Contra           -5.88         SuVe/LVe         Superior vestibular nucleus         3         1 (psi, 2 contra           -6.24-(-7.08)         Gi         Gigantocellular nucleus         3         1 (psi, 2 contra           -7.08         Sol         Soliary tract         1         (psi           -1.22         M1         Prinary motor cortex         1         Contra           -3.28         mRt         Mesencephalic reticular formation         3         Contra           -3.28         mRt         Mesencephalic reticular nucleus, audal part         2 <t< td=""><td></td><td></td><td>-4.04</td><td>Su3</td><td>Supraoculomotor periaqueductal gray</td><td>1</td><td>lpsi</td></t<>			-4.04	Su3	Supraoculomotor periaqueductal gray	1	lpsi
-4.24         Pig/Pn0         Reticuloregmental nucleus, or al part         1         Contra           -4.48-(-4.60)         Pn0         Pontine reticular nucleus, oral part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, oral part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, acidal part         1         Contra           -5.58         SuVe/V         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.58         SuVe/V         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.58         SuVe/V         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.58         SuVe/V         Superior vestibular nucleus/lateral vestibular nucleus         1         Ipsi           -6.56         G1         C1 adrenaline cells         1         Ipsi           -7.08         Sol         Soltary tract         1         Ipsi           -1.22         M1         Prinary motor cortex         1         Contra           -3.28         mRt         Secondary motor cortex         1         Contra           -3.28         mRt         Pontine reticular			-4.24	mRT	Mesencephalic reticular formation	1	Contra
Female         -448-(-4.60)         Pn0         Pontine reticular nucleus, caudal part         7         1 ipsi, 6 contra           -5.20         PnC         Pontine reticular nucleus, caudal part         2         1 ipsi, 1 contra           -5.20         P0         Paraoliviny nucleus         1         Contra           -5.68         SuVe         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.88         SuVe/LVe         Superior vestibular nucleus         1         Contra           -5.88         -6.24-(-7.08)         Gi         Gigantocellular vestibular nucleus         3         1 ipsi, 2 contra           -6.24-(-7.08)         SpVe         Spiant vestibular nucleus         3         1 ipsi, 2 contra           -6.96         C1         C1 adrenaline cells         1         Ipsi           -7.08         Sol         Solitary tract         1         Contra           -1.22         M2         Secondary motor cortex         1         Contra           -3.08         p1Rt         Pi reticular formation         2         Ipsi           -3.28         RRC         Red nucleus, paraicellular part         2         Contra           -3.28         RPC         Red nucleus, paraicellular part			-4.24	PTq/PnO	Reticulotegmental nucleus of the pons/pontine reticular nucleus, oral part	1	Contra
-5.20         PnC         Pontine reticular nucleus, caudal part         2         1 ipsi, 1 contra           -5.20         P0         Paraolivary nucleus         1         Contra           -5.88         SuVe         Superior vestibular nucleus/lateral vestibular nucleus         1         Contra           -5.88         SuVe/LVe         Superior vestibular nucleus         5         2 ipsi, 3 contra           -5.88         GI         Gigantocellular vestibular nucleus         5         2 ipsi, 3 contra           -6.96         C1         C1 adrenaline cells         1         Ipsi           -6.96         C1         C1 adrenaline cells         1         Ipsi           -7.08         Sol         Soltary tract         1         Contra           -1.22         M2         Secondary motor cortex         1         Contra           -3.08         PIRt         P1 reticular formation         3         Contra           -3.28         RMC         Red nucleus, nagnocellular part         1         Contra           -3.28         RPC         Pontine reticular nucleus, caudal part         2         Contra           -5.20         PnR         Pontine reticular nucleus, caudal part         2         Contra           -5.20 <td></td> <td></td> <td>-4.48-(-4.60)</td> <td>PnŐ</td> <td>Pontine reticular nucleus, oral part</td> <td>7</td> <td>1 ipsi, 6 contra</td>			-4.48-(-4.60)	PnŐ	Pontine reticular nucleus, oral part	7	1 ipsi, 6 contra
-5.20P0Paraolivary nucleus1Contra-5.68SuVeSuperior vestibular nucleus/ateral vestibular nucleus1Contra-5.68SuVe/LVeSuperior vestibular nucleus/ateral vestibular nucleus52 ipsi, 3 contra-5.88-(-7.08)GGigantocellular vestibular nucleus31 ipsi, 2 contra-6.24-(-7.08)SpVespinal vestibular nucleus31 ipsi, 2 contra-6.24-(-7.08)SolC1 adrenaline cells1lpsi-7.08SolSoltary trat1Contra-7.08SolSoltary trat1Contra-7.28M1Primary motor cortex1Contra-3.28mRtMesencephalic reticular formation3Contra-3.28mRtMesencephalic reticular formation2lpsi-3.28RPCRed nucleus, paroicellular part1Contra-5.20PnCPontine reticular nucleus1Contra-5.20PnRPontine reticular nucleus, caudal part2Contra-5.20PnRPontine reticular nucleus, caudal part1Contra-6.44GiGiGigantocellular part1Contra-6.75GiGigantocellular nucleus, caudal part2Contra-6.76GiGigantocellular nucleus, caudal part2Contra-7.88MVeMCMedial vestibular nucleus, caudal part2Contra-7.81MithPrimary somatosensory cortex, barrel/primary somatosen			-5.20	PnC	Pontine reticular nucleus, caudal part	2	1 ipsi, 1 contra
Female         -5.68         SuVe         Superior vestibular nucleus/ateral vestibular nucleus         1         Contra           -5.88         SuVe/LVe         Superior vestibular nucleus/ateral vestibular nucleus         3         1 jpsi, 2 contra           -6.26/1-(7.08)         Gi         Gigantocellular vestibular nucleus         3         1 jpsi, 2 contra           -6.96         C1         C1 adrenaline cells         1         1 jpsi, 2 contra           -7.08         Sol         Solitary tract         1         Contra           -7.08         Sol         Secondary motor cortex         1         Contra           -7.08         Sol         Secondary motor cortex         1         Contra           -3.08         p1Rt         P1 reticular formation         3         Contra           -3.28         mRC         Red nucleus, nagnocellular part         Contra         Contra           -3.28         mRC         Red nucleus, nagnocellular part         Contra         Contra           -5.20         PnC         Pontine reticular nucleus, caudal part         Contra         Contra           -5.20         PnC         Pontine reticular nucleus, caudal part         Contra         Contra           -6.84         MVeMC         Medial vestibular nucleu			-5.20	PO	Paraolivary nucleus	1	Contra
-5.88SuVe/LVeSuperior vestibular nucleus/lateral vestibular nucleus1Contra-5.88-(-7.08)GiGigantocellular vestibular nucleus52 ipsi, 3 contra-6.24-(-7.08)SpVespinal vestibular nucleus31 ipsi, 2 contra-6.24-(-7.08)SolC1C1 adrenaline cells1lpsi-7.08SolSolitary trat1Contra-7.08SolSolitary trat1Contra-7.08NNucleusSolodary motor cortex1Contra-3.08P1RtP1 reticular formation3Contra-3.28RRCRed nucleus, magnocellular part5Contra-3.28RPCRed nucleus, sangnocellular part5Contra-4.60PA4Paratrochear nucleus, carda part2Contra-5.20PnCPontine reticular nucleus, carda part1Ipsi-5.20PnCPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus, carda part2Contra-5.20PnRPontine raphe nucleus, carda part1Ipsi-6.64GiGigantocellular vestibular nucleus, barrel/primary somatosensory cortex, barrel/primary somatosenso			-5.68	SuVe	Superior vestibular nucleus	1	Contra
Female         -5.88-(-7.08)         Gi         Gigantocellular vestibular nucleus         5         2 ipsi, 3 contra           -6.24-(-7.08)         SpVe         spinal vestibular nucleus         3         1 ipsi, 2 contra           -6.96         C1         C1 adrenaline cells         1         lpsi           -7.08         Sol         Solitary tract         1         lpsi           -7.08         Sol         Solitary tract         1         Contra           -1.22         M1         Primary motor cortex         1         Contra           -3.08         plRt         pl reticular formation         3         Contra           -3.28         MRC         Red nucleus, magnocellular part         1         Contra           -3.28         RPC         Red nucleus, radicular part         5         Contra           -4.24-(-4.60)         Pn0         Pontine reticular nucleus, radignocellular part         5         Contra           -5.20         PnR         Pontine reticular nucleus, radignocellular part         1         Ipsi           -5.20         PnR         Pontine reticular nucleus, radignocellular part         1         Ipsi           Male         4         -0.7         RSD         Retrosplenial dysgranular cortex			-5.88	SuVe/LVe	Superior vestibular nucleus/lateral vestibular nucleus	1	Contra
Female-6.24-(-7.08)SpVespinal vestibular nucleus31 ipsi, 2 contra-6.96C1C1 adrenaline cells1lpsi-7.08SolSolitary tract1lpsi-7.08SolSolitary tract1lpsi-7.08SolSolitary tract1lpsi-7.08M2Secondary motor cortex1Contra-3.08p1Rtp1 reticular formation3Contra-3.28mRtMesencephalic reticular formation2lpsi-3.28RPCRed nucleus, magnocellular part5Contra-3.28RPCRed nucleus, angnocellular part2Contra-3.28RPCRed nucleus, angnocellular part2Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, caudal part2Contra-4.60Pa4Paratrochlear nucleus, caudal part2Contra-5.20PnRPontine reticular nucleus, caudal part1IpsiMale4-0.7RSDRetrosplenial dysgranular cortex, barrel1IpsiMale5-5.23PnCPontine reticular nucleus, andal part1IpsiMale5-5.23PnCPontine reticular nucleus, barrel/primary somatosensory cortex, barrel1IpsiMale6-4.16mRtMesencephalic reticular nucleus, caudal part2ContraMale6-5.23PnCPontine reticular nucleus, caudal part2Contra			-5.88-(-7.08)	Gi	Gigantocellular vestibular nucleus	5	2 ipsi, 3 contra
Female-6.96C1C1 adrenaline cells1Ipsi-7.08SolSolitary tract1Ipsi-7.08SolSolitary tract1Ipsi-7.08SolSolitary tract1Contra-1.22M1Primary motor cortex1Contra-3.08p1Rtp1 reticular formation3Contra-3.28RRCRed nucleus, magnocellular part1Contra-3.28RPCRed nucleus, magnocellular part5Contra-4.60Pa4Paratrochlear nucleus, oral part2Contra-5.20PnCPontine reticular nucleus, calad part2Contra-5.20PnRPontine reticular nucleus, angnocellular part1Contra-5.20PnRPontine reticular nucleus, calad part2Contra-5.20PnRPontine reticular nucleus, angnocellular part1Contra-5.20PnRPontine reticular nucleus, angnocellular part1Contra-5.20PnRPontine reticular nucleus, magnocellular part1Contra-5.20PnRPontine reticular nucleus, magnocellular part1Ipsi-5.21PnRPinary somatosensory cortex, barrel/primary somatosensory cortex, porterIpsi <td< td=""><td></td><td>-6.24-(-7.08)</td><td>SpVe</td><td>spinal vestibular nucleus</td><td>3</td><td>1 ipsi, 2 contra</td></td<>			-6.24-(-7.08)	SpVe	spinal vestibular nucleus	3	1 ipsi, 2 contra
Female3-7.08SolSolSolitary tract1IpsiFemale3-1.22M1Primary motor cortex1Contra-1.22M2Secondary motor cortex1Contra-3.08p1Rtp1 reticular formation2lpsi-3.28mRtMesencephalic reticular formation2lpsi-3.28mRCRed nucleus, magnocellular part5Contra-3.28RPCRed nucleus, parvicellular part2Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60PAParatrochlear nucleus, caudal part2Contra-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnCPontine raphe nucleusnull upsilpsi-5.20PnCPontine raphe nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus, magnocellular part1Ipsi-5.20PnRPontine raphe nucleus, magnocellular part1Ipsi-5.20PnRPontine raphe nucleus, magnocellular part1Ipsi-6.38S1BF/S1ULpPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1IpsiMale5-5.23PnCPortine reticular nucleus, audal part2Contra-6.64GiGi Gigantocellular vestibul			-6.96	C1	C1 adrenaline cells	1	lpsi
Female3-1.22M1Primary motor cortex1Contra-1.22M2Secondary motor cortex1Contra-3.08p1Rtp1 reticular formation3Contra-3.28mRtMesencephalic reticular formation2lpsi-3.28mRtMesencephalic reticular formation2lpsi-3.28RMCRed nucleus, magnocellular part1Contra-3.28RPCRed nucleus, magnocellular part5Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Partorchlear nucleus1lpsi-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus1lpsi-5.20PnRPontine raphe nucleus1Contra-5.20PnRPontine raphe nucleus1lpsi-5.20PnRPontine raphe nucleus, magnocellular part1Contra-5.20PnRPontine raphe nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-0.7S1HLPrimary somatosensory cortex, harrel/primary somatosensory cortex, upper lip1lpsiMale5-5.23PnCPortine reticular nucleus, adal part2Contra-6.64GiGigantocellular vestibular nucleus1ContraContraMale6-4.16 <td></td> <td></td> <td>-7.08</td> <td>Sol</td> <td>Solitary tract</td> <td>1</td> <td>Ipsi</td>			-7.08	Sol	Solitary tract	1	Ipsi
-1.22M2Secondary motor cortex1Contra-3.08p1Rtp1 reticular formation3Contra-3.08mRtMesencephalic reticular formation2lpsi-3.28mRtMesencephalic reticular formation2lpsi-3.28RPCRed nucleus, parvicellular part1Contra-3.28RPCRed nucleus, parvicellular part2Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus1lpsi-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine reticular nucleus, magnocellular part1Contra-5.20PnRPontine raphe nucleus1lpsi-5.88MVeMCMedial vestibular nucleus, magnocellular part1Contra-6.83S1BF/S1ULpPrimary somatosensory cortex, barrel1lpsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1lpsiMale5-5.23PnCPontine reticular nucleus1lpsiMale6-4.16GiGigantocellular vestibular nucleus1Contra-6.64GiGigantocellular vestibular nucleus1Contra-7.78MdVMedullary reticular nucleus, endal part1Contra-7.78MdVMedullary reticular nucleus, endel part1Contra-7.78<	Female	3	-1.22	M1	Primary motor cortex	1	Contra
-3.08p1Rtp1 reticular formation3Contra-3.28mRtMesencephalic reticular formation2lpsi-3.28mRtMesencephalic reticular formation2lpsi-3.28RMCRed nucleus, magnocellular part1Contra-3.28RPCRed nucleus, parvicellular part5Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus, cal part2Contra-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine reticular nucleus, caudal part1lpsi-5.20PnRPontine reticular nucleus, magnocellular part1Contra-5.20PnRPontine reticular nucleus, magnocellular part1Contra-5.20PnRPontine raphe nucleus1lpsi-5.20S1BF/S1ULPPrimary somatosensory cortex, barrel1lpsi-0.7S1HLPrimary somatosensory cortex, barrel1lpsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1lpsi-6.97GiGigantocellular vestibular nucleus, caudal part2Contra-6.64GiGigantocellular vestibular nucleus1Contra-6.64GiGigantocellular vestibular nucleus1Contra-7.78MdVMedullar vestibular nucleus, erutel part1Contra-7.78 <td< td=""><td></td><td></td><td>-1.22</td><td>M2</td><td>Secondary motor cortex</td><td>1</td><td>Contra</td></td<>			-1.22	M2	Secondary motor cortex	1	Contra
-3.28mRtMesencephalic reticular formation2Ipsi-3.28RMCRed nucleus, magnocellular part1Contra-3.28RPCRed nucleus, parvicellular part5Contra-3.28RPCRed nucleus, parvicellular nucleus, oral part2Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus, caudal part2Contra-5.20PnCPontine reticular nucleus, caudal part1Ipsi-5.20PnRPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus, magnocellular part1Contra-5.88MVeMCMedial vestibular nucleus, magnocellular part1Ipsi-1.34S1BFPrimary somatosensory cortex, barrel1Ipsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-0.7S1HLPrimary somatosensory cortex, hindleg1Contra-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2Contra-6.64GiGigantocellular vestibular nucleus1ContraContra-6.64GiGigantocellular vestibular nucleus1ContraContra-6.60LVeLateral vestibular nucleus, ventral p			-3.08	p1Rt	p1 reticular formation	3	Contra
-3.28RMCRed nucleus, magnocellular part1Contra-3.28RPCRed nucleus, parvicellular part5Contra-3.28RPCRed nucleus, parvicellular part2Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus15.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine reticular nucleus, caudal part1Ipsi-5.88MVeMCMedial vestibular nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex, barrel1Ipsi0.38S1BFFPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2Contra-6.64GiGigantocellular vestibular nucleus1IpsiMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular formation1Contra-6.0LVeLateral vestibular nucleus, ventral part1Contra-7.78MdVMedullary meticular nucleus, ventral part1Contra-7.78NdVMedullary meticular nucleus, ventral part1Contra-7.78 <td></td> <td></td> <td>-3.28</td> <td>, mRt</td> <td>Mesencephalic reticular formation</td> <td>2</td> <td>lpsi</td>			-3.28	, mRt	Mesencephalic reticular formation	2	lpsi
-3.28RPCRed nucleus, parvicellular part5Contra-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus11-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus1Ipsi-5.88MVeMCMedial vestibular nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-0.7S1BFPrimary somatosensory cortex, barrel1Ipsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-0.7S1HLPrimary somatosensory cortex, hindleg1Contra-6.97GiGigantocellular vestibular nucleus1IpsiMale5-5.23PnCPontine reticular nucleus, caudal part2ContraMale6-4.16mRtMesencephalic reticular nucleus1ContraMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular nucleus, vental part1Contra-6.0LVeLateral vestibular nucleus, vental part1Contra-7.78MdVMedullary reticular nucleus, vental part1Contra			-3.28	RMC	Red nucleus, magnocellular part	1	Contra
-4.24-(-4.60)Pn0Pontine reticular nucleus, oral part2Contra-4.60Pa4Paratrochlear nucleus1-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-1.34S1BFPrimary somatosensory cortex, barrel1Ipsi-0.7S1HLPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2ContraMale6-4.16mRtMesencephalic reticular nucleus1ContraMale6-4.16mRtMesencephalic reticular nucleus1Contra-7.78MdVMedulary reticular nucleus, ventral part1Contra-7.78MdVMedulary reticular nucleus, nucleus, ventral part1Contra			-3.28	RPC	Red nucleus, parvicellular part	5	Contra
-4.60Pa4Paratrochlear nucleus1-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus1Ipsi-5.20PnRPontine raphe nucleus1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-1.34S1BFPrimary somatosensory cortex, barrel1Ipsi-0.7S1HLPrimary somatosensory cortex, hindleg1Contra-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2ContraMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular nucleus, ventral part1ContraMale77.60MdVMedulary reticular nucleus, ventral part1Contra			-4.24-(-4.60)	PnO	Pontine reticular nucleus, oral part	2	Contra
-5.20PnCPontine reticular nucleus, caudal part2Contra-5.20PnRPontine raphe nucleus1Ipsi-5.88MVeMCMedial vestibular nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-1.34S1BFPrimary somatosensory cortex, barrel1Ipsi-0.7S1BF/S1ULpPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-0.7S1HLPrimary somatosensory cortex, hindleg1Contra-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2ContraMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular nucleus, ventral part1ContraMale7.7.78MdVMedullary reticular nucleus, ventral part1Contra			-4.60	Pa4	Paratrochlear nucleus	1	
-5.20PnRPontine raphe nucleus1Ipsi-5.88MVeMCMedial vestibular nucleus, magnocellular part1ContraMale4-0.7RSDRetrosplenial dysgranular cortex2Contra-1.34S1BFPrimary somatosensory cortex, barrel1Ipsi0.38S1BF/S1ULpPrimary somatosensory cortex, barrel/primary somatosensory cortex, upper lip1Ipsi-0.7S1HLPrimary somatosensory cortex, hindleg1Contra-6.97GiGigantocellular vestibular nucleus, caudal part2ContraMale5-5.23PnCPontine reticular nucleus, caudal part2ContraMale6-4.16mRtMesencephalic reticular formation1ContraMale6-4.16mRtMesencephalic reticular nucleus, ventral part1ContraMale76.00LVeLateral vestibular nucleus, ventral part1ContraMale76.00DroDroContraContraMale77.00MdVMedulary reticular nucleus, ventral part1Contra			-5.20	PnC	Pontine reticular nucleus, caudal part	2	Contra
-5.88       MVeMC       Medial vestibular nucleus, magnocellular part       1       Contra         Male       4       -0.7       RSD       Retrosplenial dysgranular cortex       2       Contra         -1.34       S1BF       Primary somatosensory cortex, barrel       1       Ipsi         -0.7       S1BF/S1ULp       Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip       1       Ipsi         -0.7       S1HL       Primary somatosensory cortex, hindleg       1       Contra         -6.97       Gi       Gigantocellular vestibular nucleus, caudal part       2       Contra         Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular nucleus, ventral part       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular nucleus, ventral part       1       Contra         -7.78       MdV       Medulary reticular nucleus, ventral part       1       Contra			-5.20	PnR	Pontine raphe nucleus	1	lpsi
Male       4       -0.7       RSD       Retrosplenial dysgranular cortex       2       Contra         -1.34       S1BF       Primary somatosensory cortex, barrel       1       Ipsi         0.38       S1BF/S1ULp       Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip       1       Ipsi         -0.7       S1HL       Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip       1       Contra         -0.7       S1HL       Primary somatosensory cortex, hindleg       1       Contra         -6.97       Gi       Gigantocellular vestibular nucleus       1       Ipsi         Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         -7.78       MdV       Medullary reticular nucleus, ventral part       1       Contra			-5.88	MVeMC	Medial vestibular nucleus, magnocellular part	1	Contra
<ul> <li>-1.34 S1BF Primary somatosensory cortex, barrel</li> <li>1 Ipsi</li> <li>0.38 S1BF/S1ULp Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip</li> <li>-0.7 S1HL Primary somatosensory cortex, hindleg</li> <li>-0.7 Gi</li> <li>Gigantocellular vestibular nucleus</li> <li>-6.97 Gi</li> <li>Gigantocellular vestibular nucleus, caudal part</li> <li>-6.64 Gi</li> <li>Gigantocellular vestibular nucleus</li> <li>-6.64 Gi</li> <li>Gigantocellular vestibular nucleus</li> <li>-6.64 Gi</li> <li>Gigantocellular vestibular nucleus</li> <li>-6.04 Contra</li> <li>Contra</li> <li>-6.0 LVe</li> <li>Lateral vestibular nucleus, ventral part</li> <li>Contra</li> <li>-7.78 MdV</li> <li>Medullary reticular nucleus, reuch part</li> <li>Contra</li> </ul>	Male	4	-0.7	RSD	Retrosplenial dysgranular cortex	2	Contra
0.38       S1BF/S1ULp       Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip       1       Ipsi         -0.7       S1HL       Primary somatosensory cortex, hindleg       1       Contra         -6.97       Gi       Gigantocellular vestibular nucleus       1       Ipsi         Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular nucleus, ventral part       1       Contra         -6.0       LVe       Lateral vestibular nucleus, ventral part       1       Contra         -7.78       MdV       Medullary nucleus, ventral part       1       Contra	marc		-1.34	S1BF	Primary somatosensory cortex, barrel	1	lpsi
-0.7       S1HL       Primary somatosensory cortex, hindleg       1       Contra         -6.97       Gi       Gigantocellular vestibular nucleus       1       Ipsi         Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -6.64       Gi       Gigantocellular vestibular nucleus       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular nucleus, ventral part       1       Contra         Male       6       -7.78       MdV       Medullary nucleus, ventral part       1       Contra			0.38	S1BF/S1ULp	Primary somatosensory cortex, barrel/primary somatosensory cortex, upper lip	1	lpsi
-6.97       Gi       Gigantocellular vestibular nucleus       1       Ipsi         Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -6.64       Gi       Gigantocellular vestibular nucleus       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular nucleus, ventral part       1       Contra         -6.0       LVe       Lateral vestibular nucleus, ventral part       1       Contra         -7.78       MdV       Medullary reticular nucleus, ventral part       1       Contra			-0.7	S1HL	Primary somatosensory cortex, hindleg	1	Contra
Male       5       -5.23       PnC       Pontine reticular nucleus, caudal part       2       Contra         Male       6       -6.64       Gi       Gigantocellular vestibular nucleus       1       Contra         Male       6       -4.16       mRt       Mesencephalic reticular formation       1       Contra         -6.0       LVe       Lateral vestibular nucleus, ventral part       1       Contra         -7.78       MdV       Medullary reticular nucleus, ventral part       1       Contra			-6.97	Gi	Gigantocellular vestibular nucleus	1	lpsi
-6.64     Gi     Gigantocellular vestibular nucleus     1     Contra       Male     6     -4.16     mRt     Mesencephalic reticular formation     1     Contra       -6.0     LVe     Lateral vestibular nucleus     1     Contra       -7.78     MdV     Medullary reticular nucleus, ventral part     1     Contra	Male	5	-5.23	PnC	Pontine reticular nucleus, caudal part	2	Contra
Male     6     -4.16     mRt     Mesencephalic reticular formation     1     Contra       -6.0     LVe     Lateral vestibular nucleus     1     Contra       -7.78     MdV     Medullary reticular nucleus, ventral part     1     Contra       Male     7     F.00     Description antique model part     1     Contra			-6.64	Gi	Gigantocellular vestibular nucleus	1	Contra
-6.0     LVe     Lateral vestibular nucleus     1     Contra       -7.78     MdV     Medullary reticular nucleus, ventral part     1     Contra       Male     7     F.20     Decimal part     1     Contra	Male	6	-4.16	mRt	Mesencephalic reticular formation	1	Contra
-7.78 MdV Medullary reticular nucleus, ventral part 1 Contra			-6.0	LVe	Lateral vestibular nucleus	1	Contra
			-7.78	MdV	Medullary reticular nucleus, ventral part	1	Contra
indie / -5.20 Pric Pontine reticular nucleus, caudal part I Contra	Male	7	-5.20	PnC	Pontine reticular nucleus, caudal part	1	Contra
-5.88 LPGi Lateral paragigantocellular nucleus 1			-5.88	LPGi	Lateral paragigantocellular nucleus	1	

mediating *Glra3*-Cre(+) neurons receive motor input or if the ventrally located *Glra3*-Cre population have motor functions.

Traced cells were also detected in the brain, suggesting that the lumbar *Glra3*-Cre(+) neurons receive distant descending input. These brain areas included the contralateral motor cortices, ipsilateral primary somatosensory cortex, barrel area, contralateral p1 reticular formation, magnocellular and parvicellular parts of the red nucleus (RMC and RPC), ipsilateral oral and caudal part of the pontine reticular nucleus, and bilateral gigantocellular vestibular nucleus. Previous unilateral retrograde tracing from the cervical 1 and 2 segments in mouse shows a similar tracing pattern as observed in our tracing experiment (Liang et al., 2011). The RMC and reticular formations are related to analgesic functions (Prado et al., 1984; Martins and Tavares, 2017; Basile et al., 2021) and the RMC, RPC, and pontine reticular nucleus to motor functions (Morales et al., 1987; Kennedy, 1990; Basile et al., 2021). Moreover, a study in mice linked monosynaptic signaling from the motor and sensory cortices to distinct spinal dorsal and ventral interneuron populations and further to different motoric functions. Here, scant monosynaptic inputs from the

![](_page_23_Figure_2.jpeg)

**Figure 13.** The spinal *Glra3*-Cre populations receive monosynaptic information from multiple subgroups of primary afferents. *A*–*K*, Coexpression of markers (yellow) in lumbar DRG mCherry(+) traced cells (magenta). The cyan dotted circles indicate mCherry(+)marker(+) and the magenta dotted circles show examples of mCherry(+)marker(-) cells. *A*, NF200: 2 females, 2 males. *B*, TRKA: 2 females, 2 males. *C*, CGRP: 1 female, 2 males. *D*, IB4: 3 females, 1 male. *E*, TH: 4 females, 2 males. *F*, *Mrgprd*: 1 female, 2 males. *G*, *Mrgpra3*: 1 female, 2 males. *H*, SST: 2 females, 1 male. *I*, *Nppb*: 1 female, 2 males. *J*, *Trpv1*: 1 female, 2 males. *K*, *Trpm8*: 1 female, 2 males. Scale bar, 100 µm. *L*, Bar plot of the proportion of marker coexpression in mCherry(+) DRG cells. *M*, Bar plot of the occurrence of mCherry(+) in marker-expressing DRG cells. The results are shown as total percentages of overlap. *N*, Schematic illustration of a root stimulation combined patch-clamp recording, where red dots indicate *Glra3*-Cre(+) neurons. The traces in the middle are representative patch-clamp recordings of monosynaptic inputs from the different afferent fiber subtypes. The overlapping areas denote neurons that received monosynaptic inputs from multiple afferent fiber subtypes. For separate channels, see Figure 14.

motor cortex to dorsal horn neurons and from the sensory cortex to ventral neurons were observed (Ueno et al., 2018), indicating that the ventrally located *Glra3*-Cre(+) neurons probably receive monosynaptic input from the motor cortex. Collectively, we showed that the spinal *Glra3*-Cre populations receive monosynaptic descending input from brain areas involved in sensory and/ or motor functions.

#### Conclusions

Spinal GLYT2 neurons regulate itch (Foster et al., 2015), suggesting that the glycinergic system has potential as a drug target for itch. Nonetheless, thus far, the pruriceptive roles of the glycine receptor subunits have not been evaluated. Here, we successfully linked the *Glra3*-Cre populations to a pro-pruriceptive role in itch, indicating that GLRA3 may be a potential novel target for itch treatment. The spontaneous guarding behaviors observed from activating the *Glra3*-Cre populations are indicative of a role in sensory hypersensitivity (Wang and Wang, 2003; Mogil and Crager, 2004; Casarrubea et al., 2019) and raises questions regarding the hypersensitivity involvement of these populations for future investigations.

#### Methodological considerations

From the monosynaptic retrograde viral tracing, the lumbar *Glra3*-Cre populations were found to receive both inhibitory PAX2(+) and presumably excitatory, PAX2(-) input, from the lumbar segments, where the majority of the traced mCherry(+) cells were PAX2(-). However, the NEUN overlap analysis

![](_page_24_Figure_2.jpeg)

Figure 14. Spinal *Glra3*-Cre traced mCherry(+) colocalization with the marker genes and tested proteins, relating to Figure 13. Separate channel view of the different DRG markers from Figure 9. *A*–*K*, The lumbar *Glra3*-Cre traced mCherry(+) cells in the DRG (magenta). *A*′–*K*′, Marker genes and proteins. Scale bar, 100 μm.

revealed that 44% of starter cells, 79% of traced mCherry(+) cells, and 89% of virally marked *Glra3*-Cre.mCherry were NEUN(+), which can be compared with the 98% NEUN(+) overlap in the *Glra3*-Cre;*tdTomato* cells. The decrease in overlap may indicate that the viral injections affect expressional patterns in the infected cells, and therefore, the PAX2(+) overlap in the starter and traced cells may be underestimated.

### References

- Akiyama T, Iodi Carstens M, Carstens E (2011) Transmitters and pathways mediating inhibition of spinal itch-signaling neurons by scratching and other counterstimuli. PLoS One 6:e22665.
- Akiyama T, Tominaga M, Davoodi A, Nagamine M, Blansit K, Horwitz A, Carstens MI, Carstens E (2013) Roles for substance P and gastrinreleasing peptide as neurotransmitters released by primary afferent pruriceptors. J Neurophysiol 109:742–748.

- Albisetti GW, Ghanem A, Foster E, Conzelmann K-K, Zeilhofer HU, Wildner H (2017) Identification of two classes of somatosensory neurons that display resistance to retrograde infection by rabies virus. J Neurosci 37: 10358–10371.
- Anderson CR, et al. (2009) The spinal cord: a Christopher and dana reeve foundation text and atlas, Ed. 1. London: Elsevier: Academic Press
- Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV (1995) Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 7:1484–1494.
- Azimi E, Reddy VB, Pereira PJS, Talbot S, Woolf CJ, Lerner EA (2017) Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol 140:447–453.e3.
- Azimi E, Reddy VB, Shade K-TC, Anthony RM, Talbot S, Pereira PJS, Lerner EA (2016) Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight 1:e89362.
- Barker PA, Mantyh P, Arendt-Nielsen L, Viktrup L, Tive L (2020) Nerve growth factor signaling and its contribution to pain. J Pain Res 13: 1223–1241.

- Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267–284.
- Basile GA, Quartu M, Bertino S, Serra MP, Boi M, Bramanti A, Anastasi GP, Milardi D, Cacciola A (2021) Red nucleus structure and function: from anatomy to clinical neurosciences. Brain Struct Funct 226:69–91.
- Bennett DJ, Gorassini M, Fouad K, Sanelli L, Han Y, Cheng J (1999) Spasticity in rats with sacral spinal cord injury. J Neurotrauma 16:69–84.
- Berrocal YA, Almeida VW, Puentes R, Knott EP, Hechtman JF, Garland M, Pearse DD (2014) Loss of central inhibition: implications for behavioral hypersensitivity after contusive spinal cord injury in rats. Pain Res Treat 2014:178278.
- Beyer C, Roberts LA, Komisaruk BR (1985) Hyperalgesia induced by altered glycinergic activity at the spinal cord. Life Sci 37:875–882.
- Bourane S, et al. (2015) Gate control of mechanical itch by a subpopulation of spinal cord interneurons. Science 350:550–554.
- Casarrubea M, Aiello S, Santangelo A, Di Giovanni G, Crescimanno G (2019) Different representation procedures originated from multivariate temporal pattern analysis of the behavioral response to pain in Wistar rats tested in a hot-plate under morphine. Brain Sci 9:233.
- Ceder MM, Weman HM, Johansson E, Henriksson K, Magnusson KA, Roman E, Lagerström MC (2023) The glycine receptor alpha 3 subunit mRNA expression shows sex-dependent differences in the adult mouse brain. BMC Neurosci 24:32.
- Cioffi CL (2018) Modulation of glycine-mediated spinal neurotransmission for the treatment of chronic pain. J Med Chem 61:2652–2679.
- Djouhri L, Lawson SN (2004) Abeta-fiber nociceptive primary afferent neurons: a review of incidence and properties in relation to other afferent A-fiber neurons in mammals. Brain Res Brain Res Rev 46:131–145.
- Doi-Saika M, Tokunaga A, Senba E (1997) Intradermal 5-HT induces Fos expression in rat dorsal horn neurons not via 5-HT3 but via 5-HT2A receptors. Neurosci Res 29:143–149.
- Dutertre S, Becker C-M, Betz H (2012) Inhibitory glycine receptors: an update. J Biol Chem 287:40216–40223.
- Foster E, et al. (2015) Targeted ablation, silencing, and activation establish glycinergic dorsal horn neurons as key components of a spinal gate for pain and itch. Neuron 85:1289–1304.
- Freitag FB, Ahemaiti A, Jakobsson JET, Weman HM, Lagerström MC (2019) Spinal gastrin releasing peptide receptor expressing interneurons are controlled by local phasic and tonic inhibition. Sci Rep 9:16573.
- Freitag FB, Ahemaiti A, Weman HM, Ambroz K, Lagerström MC (2021) Targeting barrel field spiny stellate cells using a vesicular monoaminergic transporter 2-Cre mouse line. Sci Rep 11:3239.
- Gatto G, Bourane S, Ren X, Di Costanzo S, Fenton PK, Halder P, Seal RP, Goulding MD (2021) A functional topographic map for spinal sensorimotor reflexes. Neuron 109:91–104.e5.
- Groemer TW, Triller A, Zeilhofer HU, Becker K, Eulenburg V, Becker CM (2022) Nociception in the glycine receptor deficient mutant mouse spastic. Front Mol Neurosci 15:832490.
- Gupta K, Harvima IT (2018) Mast cell-neural interactions contribute to pain and itch. Immunol Rev 282:168–187.
- Han N, Zu JY, Chai J (2012) Spinal bombesin-recognized neurones mediate more nonhistaminergic than histaminergic sensation of itch in mice. Clin Exp Dermatol 37:290–295.
- Häring M, et al. (2018) Neuronal atlas of the dorsal horn defines its architecture and links sensory input to transcriptional cell types. Nat Neurosci 21: 869–880.
- Harvey RJ, et al. (2004) Glyr alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304:884887.
- Harvey VL, Caley A, Müller UC, Harvey RJ, Dickenson AH (2009) A selective role for alpha3 subunit glycine receptors in inflammatory pain. Front Mol Neurosci 2:14.
- Heinke B, Ruscheweyh R, Forsthuber L, Wunderbaldinger G, Sandkühler J (2004) Physiological, neurochemical and morphological properties of a subgroup of GABAergic spinal lamina II neurones identified by expression of green fluorescent protein in mice. J Physiol 560:249266.
- Hu H-J, Gereau RW (2003) ERK integrates PKA and PKC signaling in superficial dorsal horn neurons. II. Modulation of neuronal excitability. J Neurophysiol 90:1680–1688.
- Hu H-J, Gereau RW (2011) Metabotropic glutamate receptor 5 regulates excitability and Kv4.2-containing K+ channels primarily in excitatory neurons of the spinal dorsal horn. J Neurophysiol 105:3010–3021.
- Huang J, et al. (2018) Circuit dissection of the role of somatostatin in itch and pain. Nat Neurosci 21:707–716.

- Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI, Han S-K (2009) TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A 106:11330–11335.
- Jinks SL, Carstens E (2000) Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. J Neurophysiol 84:616–627.
- Kennedy PR (1990) Corticospinal, rubrospinal and rubro-olivary projections: a unifying hypothesis. Trends Neurosci 13:474–479.
- Krashes MJ, Koda S, Ye C, Rogan SC, Adams AC, Cusher DS, Maratos-Flier E, Roth BL, Lowell BB (2011) Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest 121:1424–1428.
- Kupari J, Ernfors P (2023) Molecular taxonomy of nociceptors and pruriceptors. Pain 164:1245–1257.
- LaMotte RH, Shimada SG, Sikand P (2011) Mouse models of acute, chemical itch and pain in humans. Exp Dermatol 20:778–782.
- Larsson M (2017) Pax2 is persistently expressed by GABAergic neurons throughout the adult rat dorsal horn. Neurosci Lett 638:96–101.
- Lein ES, et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. Nature 445:168–176.
- Li L, et al. (2011) The functional organization of cutaneous low-threshold mechanosensory neurons. Cell 147:1615–1627.
- Li T, Mamillapalli R, Ding S, Chang H, Liu Z-W, Gao X-B, Taylor HS (2018) Endometriosis alters brain electrophysiology, gene expression and increases pain sensitization, anxiety, and depression in female mice. Biol Reprod 99:349–359.
- Liang H, Paxinos G, Watson C (2011) Projections from the brain to the spinal cord in the mouse. Brain Struct Funct 215:159–186.
- Liu Q, et al. (2009) Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139:1353–1365.
- Liu Q, Sikand P, Ma C, Tang Z, Han L, Li Z, Sun S, LaMotte RH, Dong X (2012) Mechanisms of itch evoked by β-alanine. J Neurosci 32:14532– 14537.
- Lynch JW (2004) Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 84:1051–1095.
- Manzke T, et al. (2010) Serotonin receptor 1A-modulated phosphorylation of glycine receptor α3 controls breathing in mice. J Clin Invest 120:4118–4128.
- Mariqueo T (2020) The expression of glycine receptor α3 subunit is differentially regulated in different types of pain. J Neurol Neurobiol 6:1-4.
- Martins I, Tavares I (2017) Reticular formation and pain: the past and the future. Front Neuroanat 11:51.
- McCoy ES, Taylor-Blake B, Zylka MJ (2012) CGRPα-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch. PLoS One 7:e36355.
- McCracken LM, Lowes DC, Salling MC, Carreau-Vollmer C, Odean NN, Blednov YA, Betz H, Harris RA, Harrison NL (2017) Glycine receptor a3 and a2 subunits mediate tonic and exogenous agonist-induced currents in forebrain. Proc Natl Acad Sci U S A 114:E7179–E7186.
- Meltzer S, Santiago C, Sharma N, Ginty DD (2021) The cellular and molecular basis of somatosensory neuron development. Neuron 109:3736–3757.
- Mishra SK, Tisel SM, Orestes P, Bhangoo SK, Hoon MA (2011) TRPV1-lineage neurons are required for thermal sensation. EMBO J 30:582–593.
- Mogil JS, Crager SE (2004) What should we be measuring in behavioral studies of chronic pain in animals? Pain 112:12–15.
- Morales F, Engelhardt J, Soja P (1987) Motoneuron properties during motor inhibition produced by microinjection of carbachol into the pontine reticular formation of the decerebrate cat. J Neurophysiol 57:1118–1129.
- Nagi SS, et al. (2019) An ultrafast system for signaling mechanical pain in human skin. Sci Adv 5:eaaw1297.
- Nakano T, Andoh T, Lee J-B, Kuraishi Y (2008) Different dorsal horn neurons responding to histamine and allergic itch stimuli. Neuroreport 19:723–726.
- Nojima H, Simons CT, Cuellar JM, Carstens MI, Moore JA, Carstens E (2003) Opioid modulation of scratching and spinal c-fos expression evoked by intradermal serotonin. J Neurosci 23:10784–10790.
- Osakada F, Mori T, Cetin AH, Marshel JH, Virgen B, Callaway EM (2011) New rabies virus variants for monitoring and manipulating activity and gene expression in defined neural circuits. Neuron 71:617–631.
- Pan H, et al. (2019) Identification of a spinal circuit for mechanical and persistent spontaneous itch. Neuron 103:1135–1149.e6.
- Patapoutian A, Peier AM, Story GM, Viswanath V (2003) ThermoTRP channels and beyond: mechanisms of temperature sensation. Nat Rev Neurosci 4:529–539.

- Paxinos G, Franklin K (2001) *The mouse brain in stereotaxic coordinates*. San Diego: Academic Press.
- Peirs C, Patil S, Bouali-Benazzouz R, Artola A, Landry M, Dallel R (2014) Protein kinase C gamma interneurons in the rat medullary dorsal horn: distribution and synaptic inputs to these neurons, and subcellular localization of the enzyme. J Comp Neurol 522:393–413.
- Pinto V, Szúcs P, Derkach VA, Safronov BV (2008) Monosynaptic convergence of C- and adelta-afferent fibres from different segmental dorsal roots on to single substantia gelatinosa neurones in the rat spinal cord. J Physiol 586:4165–4177.
- Polgár E, Fowler JH, McGill MM, Todd AJ (1999) The types of neuron which contain protein kinase C gamma in rat spinal cord. Brain Res 833:71–80.
- Prado WA, Raghubir R, Roberts MHT (1984) Long duration antinociception induced by red nucleus stimulation in the rat. Pain 18:S329.
- Rogoz K, Andersen HH, Lagerström MC, Kullander K (2014) Multimodal use of calcitonin gene-related peptide and substance P in itch and acute pain uncovered by the elimination of vesicular glutamate transporter 2 from transient receptor potential cation channel subfamily V member 1 neurons. J Neurosci 34:14055–14068.
- San Martin LS, Armijo-Weingart L, Araya A, Yévenes GE, Harvey RJ, Aguayo LG (2021) Contribution of glyr  $\alpha$ 3 subunits to the sensitivity and effect of ethanol in the nucleus accumbens. Front Mol Neurosci 14:756607.
- Schemann M, Kugler EM, Buhner S, Eastwood C, Donovan J, Jiang W, Grundy D (2012) The mast cell degranulator compound 48/80 directly activates neurons. PLoS One 7:e52104.
- Sheng M, Greenberg ME (1990) The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4:477–485.
- Stantcheva KK, et al. (2016) A subpopulation of itch-sensing neurons marked by ret and somatostatin expression. EMBO Rep 17:585–600.
- Takazawa T, Choudhury P, Tong C-K, Conway CM, Scherrer G, Flood PD, Mukai J, MacDermott AB (2017) Inhibition mediated by glycinergic and GABAergic receptors on excitatory neurons in mouse superficial dorsal horn is location-specific but modified by inflammation. J Neurosci 37: 2336–2348.
- Todd AJ (2017) Identifying functional populations among the interneurons in laminae I-III of the spinal dorsal horn. Mol Pain 13:1744806917693003.
- Tudeau L, Acuña MA, Albisetti GW, Neumann E, Ralvenius WT, Scheurer L, Poe M, Cook JM, Johannssen HC, Zeilhofer HU (2020) Mice lacking spinal α2GABAA receptors: altered GABAergic neurotransmission,

diminished GABAergic antihyperalgesia, and potential compensatory mechanisms preventing a hyperalgesic phenotype. Brain Res 1741: 146889.

- Ueno M, Nakamura Y, Li J, Gu Z, Niehaus J, Maezawa M, Crone SA, Goulding M, Baccei ML, Yoshida Y (2018) Corticospinal circuits from the sensory and motor cortices differentially regulate skilled movements through distinct spinal interneurons. Cell Rep 23:1286– 1300.e7.
- Usoskin D, et al. (2015) Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci 18:145–153.
- Wang H-C, Cheng K-I, Chen P-R, Tseng K-Y, Kwan A-L, Chang L-L (2018) Glycine receptors expression in rat spinal cord and dorsal root ganglion in prostaglandin E2 intrathecal injection models. BMC Neurosci 19:72.
- Wang F, Flanagan J, Su N, Wang L-C, Bui S, Nielson A, Wu X, Vo H-T, Ma X-J, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22–29.
- Wang LX, Wang ZJ (2003) Animal and cellular models of chronic pain. Adv Drug Deliv Rev 55:949–965.
- Watson C, Paxinos G, Kayalioglu G, Heise C (2009) Chapter 16: atlas of the mouse spinal cord. In: *The spinal cord*, Ed 1, pp 308–379. London: Academic Press.
- Werynska K, Gingras J, Benke D, Scheurer L, Neumann E, Zeilhofer HU (2021) A Glra3 phospho-deficient mouse mutant establishes the critical role of PKA-dependent phosphorylation and inhibition of glycine receptors in spinal inflammatory hyperalgesia. Pain 162:2436–2445.
- Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J (1994) Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62:327–331.
- Yamamoto T, Yaksh TL (1993) Effects of intrathecal strychnine and bicuculline on nerve compression-induced thermal hyperalgesia and selective antagonism by MK-801. Pain 54:79.
- Yao GL, Tohyama M, Senba E (1992) Histamine-caused itch induces Fos-like immunoreactivity in dorsal horn neurons: effect of morphine pretreatment. Brain Res 599:333–337.
- Zeilhofer HU (2005) The glycinergic control of spinal pain processing. Cell Mol Life Sci 62:2027–2035.
- Zeisel A, et al. (2018) Molecular architecture of the mouse nervous system. Cell 174:999–1014.e22.